@NP	Repair	1
@NP	Spinal Cord Injury	11
@NP	Co-Transplantation of embryonic Stem Cell-Derived Motor Neuron	33
@NP	Co-Transplantation	33
@NP	embryonic Stem Cell-Derived Motor Neuron	55
@NP	Olfactory Ensheathing Cell ABSTRACT Background	100
@NP	Olfactory Ensheathing Cell	100
@NP	ABSTRACT Background	128
@NP	The failure of regeneration after spinal cord injury -LRB- SCI -RRB-	149
@NP	The failure	149
@NP	regeneration after spinal cord injury -LRB- SCI -RRB-	164
@NP	regeneration	164
@NP	spinal cord injury -LRB- SCI -RRB-	183
@NP	spinal cord injury	183
@NP	SCI	203
@NP	axonal demyelination and neuronal death	231
@NP	axonal demyelination	231
@NP	neuronal death	256
@NP	Cellular replacement and white matter regeneration	272
@NP	Cellular replacement	272
@NP	white matter regeneration	297
@NP	SCI repair	346
@NP	this study	361
@NP	we	373
@NP	the co-transplantation	386
@NP	olfactory ensheathing cells -LRB- OEC -RRB- and embryonic stem -LRB- ES -RRB-	412
@NP	olfactory ensheathing cells	412
@NP	OEC	441
@NP	embryonic stem	450
@NP	ES	466
@NP	cell-derived motor neurons	470
@NP	ESMN	498
@NP	contused SCI	507
@NP	Methods : OEC cultured from olfactory nerve rootlets and olfactory bulbs .	521
@NP	Methods	521
@NP	OEC cultured from olfactory nerve rootlets and olfactory bulbs	530
@NP	OEC	530
@NP	olfactory nerve rootlets and olfactory bulbs	548
@NP	olfactory nerve rootlets	548
@NP	olfactory bulbs	577
@NP	ESMN	594
@NP	mouse ES cells	625
@NP	retinoic acid and sonic hedgehog	643
@NP	retinoic acid	643
@NP	sonic hedgehog	661
@NP	Thirty female rats	677
@NP	SCI models	717
@NP	five groups	731
@NP	Control and mediuminjected groups	744
@NP	Control	744
@NP	mediuminjected groups	756
@NP	lesion	802
@NP	cell transplantation	817
@NP	OEC or ESMN or both	839
@NP	OEC or ESMN	839
@NP	both	854
@NP	the site of the lesion in other groups	882
@NP	the site	882
@NP	the lesion in other groups	894
@NP	the lesion	894
@NP	other groups	908
@NP	Results : The purity of OEC culture was 95 % .	922
@NP	Results	922
@NP	The purity of OEC culture	931
@NP	The purity	931
@NP	OEC culture	945
@NP	95 %	961
@NP	Motor neuron progenitor markers -LRB- Olig2 , Nkx6 .1 and Pax6 -RRB-	966
@NP	Motor neuron progenitor markers	966
@NP	Olig2 , Nkx6 .1 and Pax6	999
@NP	Olig2	999
@NP	Nkx6 .1 and Pax6	1006
@NP	motor neuron markers -LRB- Isl1 , Isl2 and Hb9 -RRB-	1027
@NP	motor neuron markers	1027
@NP	Isl1 , Isl2 and Hb9	1049
@NP	Isl1	1049
@NP	Isl2 and Hb9	1055
@NP	Histological analysis	1085
@NP	significantly more -LRB- P < 0.001 -RRB- spinal tissue	1119
@NP	P < 0.001	1139
@NP	P	1139
@NP	< 0.001	1140
@NP	<	1140
@NP	0.001	1141
@NP	OEC , ESMN and OEC	1176
@NP	+ ESMN groups but the OEC + ESMN group	1193
@NP	ESMN groups	1195
@NP	the OEC + ESMN group	1211
@NP	a significantly greater percentage	1235
@NP	spared tissue and myelination than other groups -LRB- P < 0.05 -RRB-	1273
@NP	spared tissue and myelination	1273
@NP	other groups -LRB- P < 0.05 -RRB-	1308
@NP	other groups	1308
@NP	P < 0.05	1322
@NP	P	1322
@NP	< 0.05	1323
@NP	<	1323
@NP	0.05	1325
@NP	The numbers of ESMN in co-transplanted group	1332
@NP	The numbers	1332
@NP	ESMN in co-transplanted group	1347
@NP	ESMN	1347
@NP	co-transplanted group	1355
@NP	ESMN group	1408
@NP	P < 0.05	1420
@NP	P	1420
@NP	< 0.05	1421
@NP	<	1421
@NP	0.05	1422
@NP	A significant -LRB- P < 0.05 -RRB- recovery of hindlimb function	1429
@NP	A significant -LRB- P < 0.05 -RRB- recovery	1429
@NP	P < 0.05	1444
@NP	P	1444
@NP	< 0.05	1445
@NP	<	1445
@NP	0.05	1446
@NP	hindlimb function	1464
@NP	rats in the transplanted groups	1498
@NP	rats	1498
@NP	the transplanted groups	1506
@NP	Conclusion	1531
@NP	We	1543
@NP	the co-transplantation of ESMN and OEC into an injured spinal cord	1557
@NP	the co-transplantation	1557
@NP	ESMN and OEC into an injured spinal cord	1583
@NP	ESMN and OEC	1583
@NP	an injured spinal cord	1601
@NP	a synergistic effect	1628
@NP	neural regeneration , ESMN survival and partial functional recovery	1660
@NP	neural regeneration	1660
@NP	ESMN survival	1681
@NP	partial functional recovery	1699
@NP	INTRODUCTION The long-term effects of spinal cord injuries -LRB- SCI -RRB-	1729
@NP	INTRODUCTION The long-term effects of spinal cord injuries	1729
@NP	INTRODUCTION	1729
@NP	The long-term effects of spinal cord injuries	1742
@NP	The long-term effects	1742
@NP	spinal cord injuries	1767
@NP	SCI	1789
@NP	the life of the patient	1812
@NP	the life	1812
@NP	the patient	1824
@NP	The main goal of basic SCI research	1837
@NP	The main goal	1837
@NP	basic SCI research	1854
@NP	new therapeutic interventions	1887
@NP	disability	1959
@NP	One of the major strategies to regenerate spinal cord	1971
@NP	One	1971
@NP	the major strategies to regenerate spinal cord	1978
@NP	spinal cord	2013
@NP	cellular transplantation	2028
@NP	The aim of cell therapy	2054
@NP	The aim	2054
@NP	cell therapy	2065
@NP	dead cells , remyelinate axons	2092
@NP	a favorable environment for axon regeneration	2138
@NP	a favorable environment	2138
@NP	axon regeneration	2166
@NP	Numerous studies	2185
@NP	the therapeutic potential of cellular transplants of various types	2217
@NP	the therapeutic potential	2217
@NP	cellular transplants of various types	2246
@NP	cellular transplants	2246
@NP	various types	2270
@NP	white matter regeneration -LSB- 1-3 -RSB-	2288
@NP	white matter regeneration	2288
@NP	1-3 -RSB-	2315
@NP	Olfactory ensheathing cell -LRB- OEC -RRB-	2321
@NP	Olfactory ensheathing cell	2321
@NP	OEC	2349
@NP	a specialized glial cell	2357
@NP	the olfactory nerve	2404
@NP	the sensory axons	2437
@NP	an array	2467
@NP	trophic factors	2479
@NP	transcription factors	2496
@NP	extracellular matrix molecules -LSB- 4-6 -RSB-	2523
@NP	extracellular matrix molecules	2523
@NP	4-6 -RSB-	2555
@NP	Combination of these properties	2561
@NP	Combination	2561
@NP	these properties	2576
@NP	OEC	2598
@NP	a candidate for spinal cord repair -LSB- 7-9 -RSB-	2602
@NP	a candidate	2602
@NP	spinal cord repair -LSB- 7-9 -RSB-	2618
@NP	spinal cord repair	2618
@NP	7-9 -RSB-	2638
@NP	The degeneration of motor neurons after SCI	2644
@NP	The degeneration	2644
@NP	motor neurons after SCI	2664
@NP	motor neurons	2664
@NP	SCI	2684
@NP	cell replacement strategies	2707
@NP	stem cell-derived motor neurons	2741
@NP	-LSB- 10 , 11 -RSB-	2773
@NP	Embryonic stem -LRB- ES -RRB- cells	2783
@NP	Embryonic stem	2783
@NP	ES	2799
@NP	several features that include replicating indefinitely without aging	2814
@NP	several features	2814
@NP	aging	2877
@NP	pluripotency	2884
@NP	rise to all different cell types in the body	2905
@NP	rise	2905
@NP	all different cell types in the body	2913
@NP	all different cell types	2913
@NP	the body	2941
@NP	12 -RSB-	2951
@NP	A multitude	2956
@NP	differentiation protocols	2980
@NP	specific neuronal and glial subtypes	3024
@NP	ES cells	3066
@NP	Spinal motor neurons and interneurons	3096
@NP	mouse ES cells	3180
@NP	retinoic acid -LRB- RA -RRB- and sonic hedgehog -LRB- Shh -RRB-	3198
@NP	retinoic acid	3198
@NP	RA	3213
@NP	sonic hedgehog	3221
@NP	Shh	3237
@NP	Some studies	3243
@NP	the potential of ES cells	3271
@NP	the potential	3271
@NP	ES cells	3288
@NP	spinal motor neuron degeneration	3307
@NP	function	3352
@NP	animals with SCI -LSB- 2 , 6 -RSB-	3364
@NP	animals	3364
@NP	SCI -LSB- 2 , 6 -RSB-	3377
@NP	embryonic stem -LRB- ES -RRB- cell-derived motor neurons -LRB- ESMN -RRB-	3398
@NP	embryonic stem -LRB- ES -RRB- cell-derived motor neurons	3398
@NP	embryonic stem	3398
@NP	ES	3414
@NP	cell-derived motor neurons	3418
@NP	ESMN	3446
@NP	transplantation	3452
@NP	spinal cord repair	3496
@NP	the majority of the ESMN	3523
@NP	the majority	3523
@NP	the ESMN	3539
@NP	the spinal cord	3563
@NP	the present study	3611
@NP	the first time	3634
@NP	we	3650
@NP	the potential use of co-transplantation of OEC and ESMN	3666
@NP	the potential use	3666
@NP	co-transplantation of OEC and ESMN	3687
@NP	co-transplantation	3687
@NP	OEC and ESMN	3709
@NP	a therapeutic strategy in spinal cord injured rats	3725
@NP	a therapeutic strategy	3725
@NP	spinal cord injured rats	3751
@NP	spinal cord	3751
@NP	rats	3771
@NP	MATERIALS AND METHODS	3778
@NP	Animals	3800
@NP	Adult female Wistar rats -LRB- n = 40 , aged 6-8 weeks and 250-300 g -RRB-	3809
@NP	Adult female Wistar rats	3809
@NP	n = 40 , aged 6-8 weeks and 250-300 g	3835
@NP	n = 40	3835
@NP	n	3835
@NP	40	3839
@NP	6-8 weeks and 250-300 g	3848
@NP	6-8 weeks	3848
@NP	250-300 g	3862
@NP	the Razi Vaccine and Serum Research Institute , Karaj , Iran	3892
@NP	the Razi Vaccine	3892
@NP	Serum Research Institute , Karaj , Iran	3913
@NP	Serum Research Institute	3913
@NP	Karaj , Iran	3939
@NP	The animals	3952
@NP	a 12 hour dark/light cycle	3983
@NP	20 °C	4013
@NP	Food and water	4019
@NP	Food	4019
@NP	water	4028
@NP	proportioned ad libitum	4038
@NP	All experimental procedures	4063
@NP	the Animal Care and Ethics	4108
@NP	the Animal Care	4108
@NP	Ethics	4128
@NP	Tehran University of Medical Sciences , Tehran , Iran	4138
@NP	Tehran University	4138
@NP	Medical Sciences , Tehran , Iran	4159
@NP	Medical Sciences	4159
@NP	Tehran , Iran	4177
@NP	SCI	4204
@NP	we	4209
@NP	30 rats in the following five groups -LRB- 6 rats in each group -RRB-	4217
@NP	30 rats	4217
@NP	the following five groups -LRB- 6 rats in each group -RRB-	4228
@NP	the following five groups	4228
@NP	6 rats in each group	4255
@NP	6 rats	4255
@NP	each group	4265
@NP	control group	4278
@NP	lesion induction without cellular transplantation	4293
@NP	lesion induction	4293
@NP	cellular transplantation	4318
@NP	medium-injected group , lesion induction and medium injection	4344
@NP	medium-injected group	4344
@NP	lesion induction	4367
@NP	medium injection	4388
@NP	OEC group , lesion induction and transplantation of OEC	4406
@NP	OEC group	4406
@NP	lesion induction and transplantation of OEC	4417
@NP	lesion induction and transplantation	4417
@NP	OEC	4457
@NP	ESMN group , lesion induction and transplantation of ESMN	4462
@NP	ESMN group	4462
@NP	lesion induction and transplantation of ESMN	4474
@NP	lesion induction and transplantation	4474
@NP	ESMN	4514
@NP	OEC + ESMN group	4532
@NP	OEC	4532
@NP	ESMN group	4538
@NP	lesion induction and co-transplantation of OEC and ESMN	4550
@NP	lesion induction and co-transplantation	4550
@NP	OEC and ESMN	4593
@NP	We	4607
@NP	10 rats	4620
@NP	OEC culture	4632
@NP	OEC cell culture .	4645
@NP	OEC	4645
@NP	cell culture	4649
@NP	establishment of OEC	4667
@NP	establishment	4667
@NP	OEC	4684
@NP	we	4689
@NP	Nash -LSB- 13 -RSB- methods	4697
@NP	Nash -LSB-	4697
@NP	some modifications -LSB- 14 -RSB-	4720
@NP	some modifications	4720
@NP	14 -RSB-	4740
@NP	brief	4748
@NP	rats	4755
@NP	overdose of ketamine and xylazine	4783
@NP	overdose	4783
@NP	ketamine and xylazine	4795
@NP	decapitation	4831
@NP	A skin incision	4845
@NP	the scalp extending from the tip of the nose to the occipital bone of the skull	4873
@NP	the scalp	4873
@NP	the tip of the nose	4898
@NP	the tip	4898
@NP	the nose	4909
@NP	the occipital bone of the skull	4921
@NP	the occipital bone	4921
@NP	the skull	4943
@NP	the nasal and frontal bones	4957
@NP	The olfactory nerve rootlets and olfactory bulbs	4999
@NP	The olfactory nerve rootlets	4999
@NP	olfactory bulbs	5032
@NP	chilled calcium	5076
@NP	magnesium free Hank 's balanced salt solution -LRB- HBSS , Sigma -RRB-	5096
@NP	magnesium	5096
@NP	free Hank 's balanced salt solution -LRB- HBSS , Sigma -RRB-	5106
@NP	free Hank 's balanced salt solution	5106
@NP	free Hank 's	5106
@NP	HBSS	5142
@NP	Sigma	5148
@NP	The tissue	5156
@NP	all meninges and blood vessels	5183
@NP	The outer two layers of the olfactory bulb and the olfactory nerve	5215
@NP	The outer two layers	5215
@NP	the olfactory bulb and the olfactory nerve	5239
@NP	the olfactory bulb	5239
@NP	the olfactory nerve	5262
@NP	The tissues	5311
@NP	a solution of 0.25 % collagenase type IA and dispase	5356
@NP	a solution	5356
@NP	0.25 % collagenase type IA and dispase	5370
@NP	II	5408
@NP	2.4 U/ml in Puck s solution ; Roche Diagnostics , Mannheim , Germany	5412
@NP	2.4 U/ml	5412
@NP	Puck s solution ; Roche Diagnostics , Mannheim , Germany	5424
@NP	Puck s solution	5424
@NP	Roche Diagnostics , Mannheim , Germany	5441
@NP	Roche Diagnostics	5441
@NP	Mannheim , Germany	5460
@NP	DMEM/F12 -LRB- Gibco , USA -RRB- in 5 % CO2 at 37 °C for 30 minutes	5482
@NP	DMEM/F12 -LRB- Gibco , USA -RRB-	5482
@NP	DMEM/F12	5482
@NP	Gibco	5492
@NP	USA	5499
@NP	5 % CO2 at 37 °C for 30 minutes	5507
@NP	5 % CO2	5507
@NP	37 °C for 30 minutes	5517
@NP	37 °C	5517
@NP	30 minutes	5526
@NP	The tissue	5538
@NP	the dispase and collagenase activity	5595
@NP	HBSS	5654
@NP	The cell suspensions	5660
@NP	300 × g for 5 minutes	5706
@NP	300 × g	5706
@NP	5 minutes	5717
@NP	plastic cell culture flask	5743
@NP	Gibco	5783
@NP	USA	5790
@NP	10 % fetal bovine serum -LRB- FBS , Sigma -RRB-	5806
@NP	10 % fetal bovine serum	5806
@NP	FBS	5830
@NP	Sigma	5835
@NP	2 mM Lglutamine -LRB- Gibco , USA -RRB-	5843
@NP	2 mM Lglutamine	5843
@NP	Gibco	5860
@NP	USA	5867
@NP	100 IU/ml penicillin	5873
@NP	100 μg/ml streptomycin -LRB- Gibco , USA -RRB-	5898
@NP	100 μg/ml streptomycin	5898
@NP	Gibco	5922
@NP	USA	5929
@NP	Cultures	5935
@NP	37ºC	5957
@NP	a humidified atmosphere containing 95 % air and 5 % CO2 for 18 hours	5965
@NP	a humidified atmosphere	5965
@NP	95 % air and 5 % CO2 for 18 hours	6000
@NP	95 % air	6000
@NP	5 % CO2 for 18 hours	6012
@NP	5 % CO2	6012
@NP	18 hours	6023
@NP	Most of the fibroblasts and fibroblast-like cells	6033
@NP	Most	6033
@NP	the fibroblasts and fibroblast-like cells	6041
@NP	the fibroblasts	6041
@NP	fibroblast-like cells	6061
@NP	plate	6095
@NP	this first incubation period	6108
@NP	The supernatants from the culture	6138
@NP	The supernatants	6138
@NP	the culture	6160
@NP	a second set of uncoated culture flasks	6199
@NP	a second set	6199
@NP	uncoated culture flasks	6215
@NP	36 hours of incubation	6246
@NP	36 hours	6246
@NP	incubation	6258
@NP	most of the OEC	6270
@NP	most	6270
@NP	the OEC	6278
@NP	the supernatant	6298
@NP	This supernatant	6315
@NP	seed a set of poly-L-lysine -LRB- Sigma -RRB- flasks	6344
@NP	seed a set	6344
@NP	seed	6344
@NP	a set	6349
@NP	poly-L-lysine -LRB- Sigma -RRB- flasks	6358
@NP	poly-L-lysine -LRB- Sigma -RRB-	6358
@NP	poly-L-lysine	6358
@NP	Sigma	6373
@NP	flasks	6380
@NP	the OEC	6403
@NP	48 hours	6427
@NP	Cultures	6437
@NP	appropriate cell number	6462
@NP	the media	6503
@NP	every 2 days	6526
@NP	ES cell culture and differentiation .	6540
@NP	ES cell	6540
@NP	culture and differentiation	6548
@NP	ESMN	6577
@NP	previously published method using feeder-free GFP-positive CGR8 mouse ES cells	6595
@NP	previously published method	6595
@NP	feeder-free GFP-positive CGR8 mouse ES cells	6629
@NP	a Gift from Stem cells Technology	6675
@NP	a Gift	6675
@NP	Stem cells Technology	6687
@NP	Tehran , Iran	6710
@NP	Tehran	6710
@NP	Iran	6718
@NP	10 -RSB-	6725
@NP	ES cells	6730
@NP	plate	6765
@NP	ES culture medium	6774
@NP	KoDMEM	6802
@NP	Gibco	6810
@NP	USA	6817
@NP	1 % nonessential amino acids -LRB- Gibco , USA -RRB-	6840
@NP	1 % nonessential amino acids	6840
@NP	Gibco	6869
@NP	USA	6876
@NP	0.1 mM 2-mercaptoethanol -LRB- Sigma , USA -RRB-	6882
@NP	0.1 mM 2-mercaptoethanol	6882
@NP	Sigma	6908
@NP	USA	6915
@NP	2 mM L-Glutamine -LRB- Gibco , USA -RRB-	6921
@NP	2 mM L-Glutamine	6921
@NP	Gibco	6939
@NP	USA	6946
@NP	1 % Penicillin/Streptomycin -LRB- Gibco , USA -RRB-	6952
@NP	1 % Penicillin/Streptomycin	6952
@NP	Gibco	6980
@NP	USA	6987
@NP	10 % ES FBS -LRB- Gibco , USA -RRB-	6993
@NP	10 % ES FBS	6993
@NP	Gibco	7005
@NP	USA	7012
@NP	1000 μ/ml LIF -LRB- ESGRO , Chemi - Con -RRB-	7021
@NP	1000 μ/ml LIF	7021
@NP	ESGRO , Chemi - Con	7036
@NP	ESGRO , Chemi	7036
@NP	Con	7050
@NP	ES cell colonies	7062
@NP	DFK5 medium	7112
@NP	DFK5 medium	7125
@NP	DF medium	7160
@NP	DMEM/F12	7171
@NP	2 mM L-Glutamine	7198
@NP	1 % Penicillin/Streptomycin	7216
@NP	0.1 mM 2-mercaptoethanol	7243
@NP	1 % Insulin-Trasferrin-Selenium Supplement -LRB- Gibco , USA -RRB-	7269
@NP	1 %	7269
@NP	Insulin-Trasferrin-Selenium Supplement -LRB- Gibco , USA -RRB-	7271
@NP	Insulin-Trasferrin-Selenium Supplement	7271
@NP	Gibco	7311
@NP	USA	7318
@NP	a 1:1 ratio	7327
@NP	ES medium -LRB- ES cell medium without LIF and FBS	7344
@NP	ES medium -LRB- ES cell medium without LIF	7344
@NP	ES medium	7344
@NP	ES cell medium without LIF	7355
@NP	ES cell medium	7355
@NP	LIF	7378
@NP	FBS	7386
@NP	10 % Knockout Serum Replacement -LRB- Gibco , USA -RRB- -RSB-	7412
@NP	Gibco	7444
@NP	USA	7451
@NP	Embryoid Body -LRB- EB -RRB-	7465
@NP	Embryoid Body	7465
@NP	EB	7480
@NP	Medium	7485
@NP	DFK5	7508
@NP	RA -LRB- 1 μM -RRB- and Shh -LRB- 300 nM , both from Sigma , USA -RRB-	7531
@NP	RA	7531
@NP	1 μM	7535
@NP	Shh	7545
@NP	300 nM , both from Sigma , USA	7550
@NP	300 nM , both	7550
@NP	300 nM	7550
@NP	Sigma , USA	7568
@NP	EB	7584
@NP	4 days	7605
@NP	EB	7613
@NP	gelatin coated flasks	7647
@NP	serum-free DMEM/F12 medium supplemented with 1 % N2 -LRB- Gibco , USA -RRB-	7672
@NP	serum-free DMEM/F12 medium	7672
@NP	1 % N2 -LRB- Gibco , USA -RRB-	7717
@NP	1 % N2	7717
@NP	Gibco	7724
@NP	USA	7731
@NP	longer culture	7741
@NP	they	7757
@NP	3 days	7785
@NP	Neurobasal medium plus 2 % B27 supplement -LRB- Gibco , USA -RRB- and 10 % FBS	7795
@NP	Neurobasal medium plus 2 % B27 supplement -LRB- Gibco , USA -RRB-	7795
@NP	Neurobasal medium	7795
@NP	2 % B27 supplement -LRB- Gibco , USA -RRB-	7818
@NP	2 % B27 supplement	7818
@NP	Gibco	7837
@NP	USA	7844
@NP	10 % FBS	7853
@NP	Immunocytochemistry .	7862
@NP	The cells	7883
@NP	incubation in 4 % paraformaldehyde -LRB- Sigma , USA -RRB-	7907
@NP	incubation	7907
@NP	4 % paraformaldehyde -LRB- Sigma , USA -RRB-	7921
@NP	4 % paraformaldehyde	7921
@NP	Sigma	7942
@NP	USA	7949
@NP	The fixed cells	7955
@NP	PBS	7988
@NP	0.1 % Triton X-100 -LRB- Sigma , USA -RRB-	8015
@NP	0.1 % Triton X-100	8015
@NP	Sigma	8034
@NP	USA	8041
@NP	PBS	8049
@NP	buffer	8078
@NP	PBS , 1 mg/ml BSA -LRB- Sigma , USA -RRB- and 10 % goat serum -LRB- Gibco , USA	8086
@NP	PBS	8086
@NP	1 mg/ml BSA -LRB- Sigma , USA -RRB-	8091
@NP	1 mg/ml BSA	8091
@NP	Sigma	8104
@NP	USA	8111
@NP	10 % goat serum -LRB- Gibco , USA	8120
@NP	10 % goat serum	8120
@NP	Gibco	8136
@NP	USA	8143
@NP	incubation	8160
@NP	primary antibodies at 4 °C overnight	8176
@NP	primary antibodies	8176
@NP	4 °C overnight	8198
@NP	4 °C	8198
@NP	Cells	8213
@NP	PBS	8241
@NP	a species-specific secondary antibody	8264
@NP	Cultures	8303
@NP	three changes of PBS	8329
@NP	three changes	8329
@NP	PBS	8346
@NP	nucleus	8354
@NP	4	8377
@NP	fluorescent microscope	8425
@NP	The expression of p75 lowaffinity nerve growth factor receptor in OEC culture	8449
@NP	The expression	8449
@NP	p75 lowaffinity nerve growth factor receptor in OEC culture	8467
@NP	p75 lowaffinity nerve growth factor receptor	8467
@NP	OEC culture	8515
@NP	immunostaining	8545
@NP	the cells	8560
@NP	primary monoclonal mouse anti-p75 NGFR antibody -LRB- Sigma , USA -RRB-	8575
@NP	primary monoclonal mouse	8575
@NP	anti-p75 NGFR antibody -LRB- Sigma , USA -RRB-	8600
@NP	anti-p75 NGFR antibody	8600
@NP	Sigma	8624
@NP	USA	8631
@NP	secondary FITC-conjugated antimouse IgG antibody -LRB- Abcam , USA -RRB-	8640
@NP	secondary FITC-conjugated antimouse	8640
@NP	IgG antibody -LRB- Abcam , USA -RRB-	8676
@NP	IgG antibody	8676
@NP	Abcam	8690
@NP	USA	8697
@NP	The expression	8703
@NP	microtubule assassination protein 2 -LRB- MAP2 -RRB-	8721
@NP	tubulin βIII in differentiated mouse ES cells	8768
@NP	tubulin βIII	8768
@NP	mouse ES cells	8799
@NP	immunostaining	8832
@NP	the cells	8847
@NP	primary monoclonal mouse anti-MAP2 and tubulin βIII	8862
@NP	Sigma	8915
@NP	USA	8922
@NP	secondary phycoerythrinconjugated anti-mouse IgG antibody	8931
@NP	Abcam	8990
@NP	USA	8997
@NP	RNA extraction and RT-PCR analysis of gene expression .	9003
@NP	RNA extraction and RT-PCR analysis	9003
@NP	gene expression	9041
@NP	Total RNA	9058
@NP	cells using the RNX plus kit -LRB- Cinnagen , Iran -RRB-	9086
@NP	cells	9086
@NP	the RNX plus kit -LRB- Cinnagen , Iran -RRB-	9098
@NP	the RNX	9098
@NP	kit -LRB- Cinnagen , Iran -RRB-	9111
@NP	kit	9111
@NP	Cinnagen	9116
@NP	Iran	9126
@NP	Standard RT	9133
@NP	the Revert AidTM H Minus First Strand cDNA Synthesis Kit -LRB- Fermentas -RRB-	9165
@NP	the Revert AidTM H Minus First Strand cDNA Synthesis Kit	9165
@NP	the Revert AidTM H	9165
@NP	Minus First Strand cDNA Synthesis Kit	9184
@NP	Fermentas	9223
@NP	the manufacturer 's instructions	9247
@NP	the manufacturer 's	9247
@NP	PCR	9280
@NP	94 °C for 1 minute	9302
@NP	94 °C	9302
@NP	1 minute	9311
@NP	30 cycles of 94 °C for 30 s	9333
@NP	30 cycles	9333
@NP	94 °C for 30 s	9346
@NP	94 °C	9346
@NP	30 s	9355
@NP	55-63 °C for 30 s , 72 °C for 30 s and 72 °C for 10 minutes	9361
@NP	55-63 °C for 30 s	9361
@NP	55-63 °C	9361
@NP	30 s	9373
@NP	72 °C for 30 s	9379
@NP	72 °C	9379
@NP	30 s	9388
@NP	72 °C for 10 minutes	9397
@NP	72 °C	9397
@NP	10 minutes	9406
@NP	DNA fragments	9428
@NP	1.5 % agarose gel and the gels	9466
@NP	1.5 % agarose gel	9466
@NP	the gels	9487
@NP	ethidium bromide -LRB- 10 μg/ml -RRB-	9514
@NP	ethidium bromide	9514
@NP	10 μg/ml	9532
@NP	a UV transilluminator -LRB- Uvidoc , UK -RRB-	9562
@NP	a UV transilluminator	9562
@NP	Uvidoc	9585
@NP	UK	9593
@NP	The primers	9598
@NP	Table 1	9624
@NP	Surgical procedures .	9633
@NP	Surgical	9633
@NP	procedures	9642
@NP	SCI	9654
@NP	Vanicky 's method -LSB- 15 -RSB-	9676
@NP	Vanicky 's method	9676
@NP	Vanicky 's	9676
@NP	15 -RSB-	9694
@NP	brief	9702
@NP	adult female Wistar rats	9709
@NP	intraperitoneal injections	9757
@NP	ketamine -LRB- 50 mg/kg -RRB- and xylazine -LRB- 5 mg/kg -RRB-	9787
@NP	ketamine	9787
@NP	50 mg/kg	9797
@NP	xylazine	9811
@NP	5 mg/kg	9821
@NP	The spinous processes of vertebrae T10-T11	9831
@NP	The spinous processes	9831
@NP	vertebrae T10-T11	9856
@NP	a small hole -LRB- 2 mm diameter -RRB-	9891
@NP	a small hole	9891
@NP	2 mm diameter	9905
@NP	vertebral arch of T10	9935
@NP	vertebral arch	9935
@NP	T10	9953
@NP	A 2-French Fogarty catheter -LRB- Percuse , France -RRB-	9958
@NP	A 2-French Fogarty catheter	9958
@NP	Percuse	9987
@NP	France	9996
@NP	the epidural space	10022
@NP	the center of the balloon	10072
@NP	the center	10072
@NP	the balloon	10086
@NP	T8-T9 level	10108
@NP	The balloon	10121
@NP	20 μl saline for 5 minutes	10159
@NP	20 μl saline	10159
@NP	5 minutes	10176
@NP	Catheter	10187
@NP	the muscles and skin	10208
@NP	All rats	10238
@NP	antibiotic -LRB- cefazolin 50 mg/kg -RRB-	10256
@NP	antibiotic	10256
@NP	cefazolin 50 mg/kg	10268
@NP	cefazolin	10268
@NP	50 mg/kg	10278
@NP	analgesic -LRB- acetaminophen 1-2 mg/ml in drinking water -RRB-	10292
@NP	analgesic	10292
@NP	acetaminophen 1-2 mg/ml in drinking water	10303
@NP	acetaminophen 1-2 mg/ml	10303
@NP	drinking water	10330
@NP	Bladder expression	10347
@NP	two times per day	10380
@NP	two times	10380
@NP	day	10394
@NP	Urinary tract infections	10399
@NP	suspension of cefazolin	10442
@NP	suspension	10442
@NP	cefazolin	10456
@NP	12 mg/kg gentamicin	10473
@NP	Autophagia	10494
@NP	acetaminophen -LRB- 1-2 mg/ml -RRB- in drinking water	10522
@NP	acetaminophen -LRB- 1-2 mg/ml -RRB-	10522
@NP	acetaminophen	10522
@NP	1-2 mg/ml	10537
@NP	drinking water	10551
@NP	self-mutilation	10574
@NP	Hoechst	10591
@NP	OEC	10609
@NP	37 °C	10631
@NP	30 minutes	10640
@NP	cultured medium	10666
@NP	10 μg/ml	10693
@NP	Hoechst 33342 -LRB- Sigma , USA -RRB-	10702
@NP	Hoechst 33342	10702
@NP	Sigma	10717
@NP	USA	10724
@NP	transplantation	10736
@NP	-LSB- 1 , 16	10752
@NP	they	10767
@NP	several times with DMEM	10784
@NP	several times	10784
@NP	DMEM	10803
@NP	serum	10816
@NP	the same medium	10838
@NP	the spinal cord	10876
@NP	Transplantations	10910
@NP	9 days	10942
@NP	the injury -LSB- 17 -RSB-	10955
@NP	the injury	10955
@NP	17 -RSB-	10967
@NP	All animals	10972
@NP	cyclosporine -LRB- 10 mg/kg , SC -RRB-	10998
@NP	cyclosporine	10998
@NP	10 mg/kg , SC	11012
@NP	10 mg/kg	11012
@NP	SC	11022
@NP	day 8 for immunosuppression	11029
@NP	day 8	11029
@NP	immunosuppression	11039
@NP	duration of survival	11075
@NP	duration	11075
@NP	survival	11087
@NP	18 -RSB-	11097
@NP	Rats	11102
@NP	DMEM medium in medium-injected group	11116
@NP	DMEM medium	11116
@NP	medium-injected group	11131
@NP	transplants of OEC -LRB- 1 × 106 -RRB- in OEC group	11154
@NP	transplants	11154
@NP	OEC -LRB- 1 × 106 -RRB- in OEC group	11169
@NP	OEC -LRB- 1 × 106 -RRB-	11169
@NP	OEC	11169
@NP	1 × 106	11174
@NP	1 ×	11174
@NP	106	11178
@NP	OEC group	11186
@NP	ESMN -LRB- 1 × 106 -RRB- in ESMN group	11197
@NP	ESMN -LRB- 1 × 106 -RRB-	11197
@NP	ESMN	11197
@NP	1 × 106	11203
@NP	1 ×	11203
@NP	106	11207
@NP	ESMN group	11215
@NP	OEC and ESMN -LRB- each 1 × 106 -RRB- in OEC	11231
@NP	OEC and ESMN -LRB- each 1 × 106 -RRB-	11231
@NP	OEC and ESMN	11231
@NP	each 1 × 106	11245
@NP	each 1 ×	11245
@NP	106	11254
@NP	OEC	11263
@NP	ESMN group	11269
@NP	means of 5 μL Hamilton syringe	11283
@NP	means	11283
@NP	5 μL Hamilton syringe	11292
@NP	5 μL	11292
@NP	The ESMN and OEC suspension -LRB- 5 μl -RRB- or DMEM medium -LRB- 5 μl -RRB-	11315
@NP	The ESMN and OEC suspension -LRB- 5 μl -RRB-	11315
@NP	The ESMN and OEC suspension	11315
@NP	5 μl	11344
@NP	DMEM medium -LRB- 5 μl -RRB-	11353
@NP	DMEM medium	11353
@NP	5 μl	11366
@NP	the center of the syrinx	11390
@NP	the center	11390
@NP	the syrinx	11404
@NP	T9 level over a 5-minute period	11418
@NP	T9 level	11418
@NP	a 5-minute period	11432
@NP	transplantation	11457
@NP	muscles and skin	11474
@NP	rats	11507
@NP	antibiotic	11521
@NP	Locomotor function .	11533
@NP	Locomotor	11533
@NP	function	11543
@NP	Locomotor function	11553
@NP	the Basso , Beattie and Bresnahan -LRB- BBB -RRB- open-field locomotor test	11592
@NP	Basso , Beattie and Bresnahan -LRB- BBB -RRB-	11596
@NP	Basso , Beattie and Bresnahan	11596
@NP	BBB	11626
@NP	two independent observers -LSB- 19 -RSB-	11663
@NP	two independent observers	11663
@NP	19 -RSB-	11690
@NP	BBB assessments	11695
@NP	3 days	11726
@NP	injury	11739
@NP	prior to transplantation and 7 , 14 , 21 and 28 days post transplantation	11750
@NP	transplantation and 7 , 14 , 21 and 28 days	11759
@NP	Histological evaluation .	11823
@NP	the final behavioral assessment post transplantation at 28 days	11854
@NP	the final behavioral assessment post transplantation	11854
@NP	28 days	11910
@NP	rats	11919
@NP	0.1 M PBS followed by 4 % paraformaldehyde and 2.5 % glutaraldehyde in PBS	11982
@NP	0.1 M PBS	11982
@NP	4 % paraformaldehyde and 2.5 % glutaraldehyde	12004
@NP	4 % paraformaldehyde	12004
@NP	2.5 % glutaraldehyde	12028
@NP	PBS	12051
@NP	The spinal cords	12056
@NP	10 % sucrose	12118
@NP	The cords	12131
@NP	TissueTek OCT compound	12160
@NP	Serial 12 μm thick longitudinal sections	12184
@NP	μm	12194
@NP	a cryostat	12237
@NP	Poly-LLysine coated slides	12263
@NP	The slides	12291
@NP	cresyl violet-Luxol	12318
@NP	blue and silver nitrate -LRB- both from Merck , Germany -RRB-	12343
@NP	blue and silver nitrate	12343
@NP	both from Merck , Germany	12368
@NP	both	12368
@NP	Merck , Germany	12378
@NP	morphometry and cell counting	12399
@NP	sections	12430
@NP	digital camera	12456
@NP	The identified areas in individual sections	12472
@NP	The identified areas	12472
@NP	individual sections	12496
@NP	image analysis software -LRB- Image J , NIH -RRB-	12536
@NP	image analysis software	12536
@NP	Image J	12561
@NP	NIH	12570
@NP	cell counts	12587
@NP	we	12600
@NP	the number	12611
@NP	transplanted cells	12625
@NP	the longitudinal sections as Hoechst-labeled and GFP-positive cells	12647
@NP	the longitudinal sections	12647
@NP	Hoechst-labeled and GFP-positive cells	12676
@NP	OEC , ESMN and OEC + ESMN groups	12718
@NP	OEC	12718
@NP	ESMN	12723
@NP	OEC + ESMN groups	12732
@NP	fluorescent microscope	12758
@NP	Every other six slides	12782
@NP	the cell count	12823
@NP	50 slides in each animal	12855
@NP	50 slides	12855
@NP	each animal	12868
@NP	Every ten longitudinal section	12881
@NP	the spared tissue and myelinated area	12934
@NP	the spared tissue	12934
@NP	myelinated area	12956
@NP	each section	12976
@NP	the number	12990
@NP	pixel	13004
@NP	area and the total number of pixels in spinal cord segment	13036
@NP	area	13036
@NP	the total number of pixels in spinal cord segment	13045
@NP	the total number	13045
@NP	pixels in spinal cord segment	13065
@NP	pixels	13065
@NP	spinal cord segment	13075
@NP	Measurements from each section	13110
@NP	Measurements	13110
@NP	each section	13128
@NP	rat	13157
@NP	the total number of sections	13179
@NP	the total number	13179
@NP	sections	13199
@NP	Spared spinal tissue	13209
@NP	the difference	13251
@NP	the numbers	13274
@NP	pixels	13289
@NP	the area	13299
@NP	damaged tissue and the number of pixels in the whole segment -LSB- 20 -RSB-	13311
@NP	damaged tissue	13311
@NP	the number of pixels in the whole segment -LSB- 20 -RSB-	13330
@NP	the number	13330
@NP	pixels in the whole segment -LSB- 20 -RSB-	13344
@NP	pixels	13344
@NP	the whole segment -LSB- 20 -RSB-	13354
@NP	the whole segment	13354
@NP	20 -RSB-	13373
@NP	Statistical analysis .	13378
@NP	All statistical analyses	13400
@NP	standard statistics computer software -LRB- SPSS 11.5 for Windows -RRB-	13443
@NP	standard statistics computer software	13443
@NP	SPSS 11.5 for Windows	13482
@NP	SPSS 11.5	13482
@NP	Windows	13496
@NP	One-way ANOVA followed by Tukey 's post hoc test	13506
@NP	One-way ANOVA	13506
@NP	Tukey 's post hoc test	13532
@NP	Tukey 's	13532
@NP	statistical differences between the spared tissue and myelin ratio in each group	13576
@NP	statistical differences	13576
@NP	the spared tissue and myelin ratio in each group	13608
@NP	the spared tissue	13608
@NP	myelin ratio in each group	13630
@NP	myelin ratio	13630
@NP	each group	13646
@NP	BBB scores	13658
@NP	groups	13689
@NP	non-parametric analysis	13702
@NP	Kruskal-Wallis followed by Mann - Whitney U test	13727
@NP	Kruskal-Wallis	13727
@NP	Mann - Whitney U test	13754
@NP	Mann	13754
@NP	Whitney U test	13760
@NP	Whitney U	13760
@NP	test	13770
@NP	Cell numbers	13777
@NP	spinal cord	13793
@NP	transplanted groups -LRB- OEC vs co-transplant and ESMN vs co-transplant -RRB-	13808
@NP	transplanted groups	13808
@NP	OEC	13829
@NP	vs co-transplant and ESMN vs co-transplant	13833
@NP	co-transplant and ESMN	13836
@NP	co-transplant	13862
@NP	independent t-test	13896
@NP	A statistically significant difference	13916
@NP	P	13971
@NP	RESULTS Table 1 .	13980
@NP	RESULTS	13980
@NP	Table 1	13988
@NP	Specific primers	13997
@NP	PCR amplification	14023
@NP	Fig. 1 .	14043
@NP	Fig.	14043
@NP	1	14048
@NP	-LRB- A -RRB- Olfactory ensheathing	14051
@NP	A	14052
@NP	cells expressing p75	14077
@NP	cells	14077
@NP	p75	14094
@NP	-LRB- B -RRB- multiple neurites	14099
@NP	-LRB- B -RRB-	14099
@NP	multiple neurites	14103
@NP	neuronal cells emerging from aggregate	14125
@NP	neuronal cells	14125
@NP	aggregate	14154
@NP	Immunostaining of aggregates	14165
@NP	Immunostaining	14165
@NP	aggregates	14183
@NP	antibody	14214
@NP	Tubulin βIII and -LRB- C -RRB- microtubule assassination protein 2 -LRB- D -RRB-	14231
@NP	Tubulin βIII	14231
@NP	C	14249
@NP	microtubule assassination protein 2 -LRB- D -RRB-	14252
@NP	-LRB- E -RRB-	14293
@NP	The expression	14297
@NP	several neuronal genes in undifferentiated ES cells as negative cell control	14315
@NP	several neuronal genes	14315
@NP	undifferentiated ES cells as negative cell control	14341
@NP	undifferentiated ES cells	14341
@NP	negative cell control	14370
@NP	CGR8	14393
@NP	mouse spinal cord as positive control and RA + Shh treated	14400
@NP	mouse spinal cord as positive control and RA	14400
@NP	mouse spinal cord	14400
@NP	positive control and RA	14421
@NP	Shh treated	14447
@NP	Shh	14447
@NP	Fig. 2 .	14461
@NP	Fig.	14461
@NP	2	14466
@NP	-LRB- A -RRB- BBB scores for five groups .	14469
@NP	-LRB- A -RRB-	14469
@NP	BBB scores for five groups	14473
@NP	BBB scores	14473
@NP	five groups	14488
@NP	Animals	14501
@NP	contusion injury	14518
@NP	Day 0	14538
@NP	Transplants	14545
@NP	Day 9	14570
@NP	BBB scores of groups receiving transplants	14577
@NP	BBB scores	14577
@NP	groups receiving transplants	14591
@NP	groups	14591
@NP	transplants	14608
@NP	control and medium-injected groups	14654
@NP	-LRB- B -RRB- Percentage of	14690
@NP	-LRB- B -RRB-	14690
@NP	tissue and myelinated area in five groups	14715
@NP	tissue and myelinated area	14715
@NP	five groups	14745
@NP	The OEC + ESMN group	14758
@NP	The OEC	14758
@NP	ESMN group	14768
@NP	a significantly greater percentage	14783
@NP	spared tissue and myelinated area than other groups	14821
@NP	spared tissue	14821
@NP	myelinated area than other groups	14839
@NP	myelinated area	14839
@NP	other groups	14860
@NP	Bar graphs	14878
@NP	the cell counts	14894
@NP	The number of GFP-positive cells in the OEC + ESMN groups	14911
@NP	The number	14911
@NP	GFP-positive cells in the OEC + ESMN groups	14925
@NP	GFP-positive cells	14925
@NP	the OEC + ESMN groups	14947
@NP	the OEC	14947
@NP	ESMN groups	14957
@NP	that in the ESMN group	14999
@NP	that	14999
@NP	the ESMN group	15007
@NP	Fig. 3 .	15024
@NP	Fig.	15024
@NP	3	15029
@NP	Photomicrographs	15032
@NP	longitudinal sections	15052
@NP	the spinal cord	15077
@NP	the control group -LRB- A and B -RRB-	15096
@NP	the control group	15096
@NP	A and B	15115
@NP	A	15115
@NP	B	15121
@NP	the mediuminjected group -LRB- C and D -RRB-	15131
@NP	the mediuminjected group	15131
@NP	C and D	15157
@NP	C	15157
@NP	D	15163
@NP	4 weeks	15166
@NP	second surgery	15180
@NP	Slides	15196
@NP	Luxol fast blue -LRB- A and C -RRB- and silver nitrate -LRB- B and D -RRB-	15222
@NP	Luxol fast blue -LRB- A and C -RRB-	15222
@NP	Luxol	15222
@NP	A and C	15239
@NP	A	15239
@NP	C	15245
@NP	silver nitrate -LRB- B and D -RRB-	15252
@NP	silver nitrate	15252
@NP	B and D	15268
@NP	B	15268
@NP	D	15274
@NP	Large cystic cavities	15278
@NP	the injured area -LRB- Stars -RRB-	15310
@NP	the injured area	15310
@NP	Stars	15328
@NP	The white matter injury	15336
@NP	Luxol fast blue	15381
@NP	Luxol	15381
@NP	Arrows	15398
@NP	damaged area	15410
@NP	Fig. 4 .	15425
@NP	Fig.	15425
@NP	4	15430
@NP	Photomicrographs	15433
@NP	longitudinal sections	15453
@NP	the spinal cord in the OEC group 4 weeks	15478
@NP	the spinal cord	15478
@NP	the OEC group	15497
@NP	4 weeks	15511
@NP	OEC transplantation	15525
@NP	Hoechstlabeled OEC -LRB- A , stars -RRB-	15546
@NP	Hoechstlabeled OEC	15546
@NP	A , stars	15566
@NP	A	15566
@NP	stars	15569
@NP	myelin -LRB- B and C stained by Luxol fast blue , arrows -RRB-	15585
@NP	myelin	15585
@NP	B and C stained by Luxol fast blue , arrows	15593
@NP	B and C	15593
@NP	Luxol fast blue , arrows	15612
@NP	Luxol fast blue	15612
@NP	Luxol	15612
@NP	arrows	15629
@NP	Presence	15638
@NP	neuronal processes	15650
@NP	silver nitrate staining -LRB- D , arrows -RRB-	15672
@NP	silver nitrate staining	15672
@NP	D , arrows	15697
@NP	D	15697
@NP	arrows	15700
@NP	Fig. 5 .	15710
@NP	Fig.	15710
@NP	5	15715
@NP	Photomicrographs	15718
@NP	longitudinal sections	15738
@NP	the spinal cord in the ESMN group 4 weeks	15763
@NP	the spinal cord	15763
@NP	the ESMN group	15782
@NP	4 weeks	15797
@NP	transplantation	15811
@NP	GFP-positive cells -LRB- A , arrows -RRB-	15828
@NP	GFP-positive cells	15828
@NP	A , arrows	15848
@NP	A	15848
@NP	arrows	15851
@NP	spinal cord and established neuronal network	15871
@NP	spinal cord	15871
@NP	established neuronal network	15887
@NP	Myelinated area	15917
@NP	OEC and OEC + ESMN groups -LRB- B , stained by Luxol fast blue -RRB-	15948
@NP	OEC	15948
@NP	OEC + ESMN groups -LRB- B , stained by Luxol fast blue -RRB-	15956
@NP	OEC + ESMN groups	15956
@NP	B , stained by Luxol fast blue	15975
@NP	B	15975
@NP	Luxol fast blue	15989
@NP	Luxol	15989
@NP	Neuronal network	16007
@NP	silver nitrate	16035
@NP	C , arrows	16051
@NP	C	16051
@NP	arrows	16054
@NP	OEC cell culture .	16064
@NP	OEC	16064
@NP	cell culture	16068
@NP	p75	16085
@NP	a receptor found on the external surface of the plasma membranes of OEC	16092
@NP	a receptor	16092
@NP	the external surface of the plasma membranes of OEC	16112
@NP	the external surface	16112
@NP	the plasma membranes of OEC	16136
@NP	the plasma membranes	16136
@NP	OEC	16160
@NP	the purity of the cell cultures and number of OEC obtained	16165
@NP	the purity	16165
@NP	the cell cultures and number of OEC obtained	16179
@NP	the cell cultures and number	16179
@NP	OEC obtained	16211
@NP	OEC	16211
@NP	the immunofluorescently labeled cell types	16252
@NP	The purity of OEC culture by this separation procedure	16296
@NP	The purity	16296
@NP	OEC culture by this separation procedure	16310
@NP	OEC culture	16310
@NP	this separation procedure	16325
@NP	95 % -LRB- Fig. 1A -RRB-	16355
@NP	95 %	16355
@NP	Fig. 1A	16360
@NP	ES cell differentiation .	16370
@NP	ES	16370
@NP	cell differentiation	16373
@NP	Two days after partial trypsinization of treated EB , many of aggregates	16395
@NP	Two days	16395
@NP	partial trypsinization of treated EB , many of aggregates	16410
@NP	partial trypsinization	16410
@NP	EB , many of aggregates	16444
@NP	EB	16444
@NP	many of aggregates	16448
@NP	many	16448
@NP	aggregates	16456
@NP	extensive outgrowth of neuritis	16476
@NP	extensive outgrowth	16476
@NP	neuritis	16499
@NP	Neurite outgrowth	16509
@NP	many points	16537
@NP	the perimeter	16555
@NP	aggregate forming a dense , tangled collection of neuritis -LRB- Fig. 1B -RRB-	16572
@NP	aggregate	16572
@NP	a dense , tangled collection of neuritis -LRB- Fig. 1B -RRB-	16590
@NP	a dense , tangled collection	16590
@NP	neuritis -LRB- Fig. 1B -RRB-	16621
@NP	neuritis	16621
@NP	Fig. 1B	16631
@NP	the neuron-like cells and process	16666
@NP	neuronassociated proteins	16708
@NP	cultures	16735
@NP	antibodies to class III β-tubulin and MAP2 -LRB- Fig. 1C and D -RRB-	16762
@NP	antibodies to class III β-tubulin	16762
@NP	antibodies	16762
@NP	class III β-tubulin	16776
@NP	MAP2 -LRB- Fig. 1C and D -RRB-	16800
@NP	MAP2	16800
@NP	Fig. 1C and D	16806
@NP	Fig. 1C	16806
@NP	D	16818
@NP	expression of neuronal gene	16838
@NP	expression	16838
@NP	neuronal gene	16852
@NP	ES cultures	16884
@NP	we	16897
@NP	the expression	16909
@NP	Olig2 , Pax6 , Nkx6 .1 , Isl1 , Isl2 , Hb9 , Lim1 , Lim2 , GFAP and OMG	16927
@NP	Olig2	16927
@NP	Pax6	16934
@NP	Nkx6 .1	16940
@NP	Isl1 , Isl2 , Hb9 , Lim1 , Lim2 , GFAP and OMG	16948
@NP	RT-PCR -LRB- Fig. 1E -RRB-	16993
@NP	RT-PCR	16993
@NP	Fig. 1E	17001
@NP	The results	17011
@NP	motor neuron progenitor markers -LRB- Olig2 , Nkx6 .1 and Pax6 -RRB-	17037
@NP	motor neuron progenitor markers	17037
@NP	Olig2 , Nkx6 .1 and Pax6	17070
@NP	Olig2	17070
@NP	Nkx6 .1 and Pax6	17077
@NP	the expression of Pax6 and Olig2	17113
@NP	the expression	17113
@NP	Pax6 and Olig2	17131
@NP	that of Nkx6 .1	17162
@NP	that	17162
@NP	Nkx6 .1	17170
@NP	Motor neuron markers -LRB- Isl1 , Isl2 and Hb9 -RRB-	17178
@NP	Motor neuron markers	17178
@NP	Isl1 , Isl2 and Hb9	17200
@NP	Isl1	17200
@NP	Isl2 and Hb9	17206
@NP	expression of Isl1 and Hb9	17240
@NP	expression	17240
@NP	Isl1 and Hb9	17254
@NP	that of Isl2	17283
@NP	that	17283
@NP	Isl2	17291
@NP	Interneuron markers -LRB- Lim1 and Lim2 -RRB-	17297
@NP	Interneuron markers	17297
@NP	Lim1 and Lim2	17318
@NP	Lim1	17318
@NP	Lim2	17327
@NP	Lim1	17352
@NP	a higher expression	17361
@NP	Astrocyte -LRB- GFAP -RRB- and oligodendrocyte -LRB- OMG -RRB- markers	17382
@NP	Astrocyte -LRB- GFAP -RRB-	17382
@NP	Astrocyte	17382
@NP	GFAP	17393
@NP	oligodendrocyte -LRB- OMG -RRB- markers	17403
@NP	oligodendrocyte	17403
@NP	OMG	17420
@NP	markers	17425
@NP	low levels	17451
@NP	Recovery of hindlimb function .	17463
@NP	Recovery	17463
@NP	hindlimb function	17475
@NP	BBB score	17494
@NP	three and nine days post injury and at weekly intervals	17517
@NP	three and nine days	17517
@NP	weekly intervals	17556
@NP	day 9	17586
@NP	the same day	17596
@NP	animals	17610
@NP	transplantation	17649
@NP	The criteria for inclusion in this study	17666
@NP	The criteria	17666
@NP	inclusion in this study	17683
@NP	inclusion	17683
@NP	this study	17696
@NP	the animal	17717
@NP	0-2	17739
@NP	day nine	17746
@NP	Figure 2A	17756
@NP	average BBB scores	17778
@NP	the post injury and post transplantation period	17804
@NP	There	17853
@NP	no significant difference in average BBB scores	17863
@NP	no significant difference	17863
@NP	average BBB scores	17892
@NP	transplantation among 5 groups -LRB- P > 0.05 -RRB-	17920
@NP	transplantation	17920
@NP	5 groups -LRB- P > 0.05 -RRB-	17942
@NP	5 groups	17942
@NP	P > 0.05	17952
@NP	P	17952
@NP	> 0.05	17953
@NP	>	17953
@NP	0.05	17954
@NP	transplantation	17971
@NP	a significant recovery of hindlimb function	17988
@NP	a significant recovery	17988
@NP	hindlimb function	18014
@NP	rats	18048
@NP	the transplanted groups	18056
@NP	medium-injected and control groups -LRB- P < 0.05 -RRB-	18094
@NP	medium-injected and control groups	18094
@NP	P < 0.05	18130
@NP	P	18130
@NP	< 0.05	18131
@NP	<	18131
@NP	0.05	18132
@NP	The mean recovery score	18139
@NP	OEC , ESMN and OEC + ESMN groups 4 weeks after transplantation were 7.33	18166
@NP	OEC , ESMN and OEC + ESMN groups 4 weeks	18166
@NP	OEC , ESMN and OEC	18166
@NP	ESMN groups 4 weeks	18186
@NP	ESMN groups	18186
@NP	4 weeks	18198
@NP	transplantation	18212
@NP	7.33	18233
@NP	± 1.03 -LRB- range 7-9 -RRB-	18238
@NP	± 1.03	18238
@NP	range 7-9	18246
@NP	,7.5 ± 0.83 -LRB- range 7-9 -RRB-	18256
@NP	,7.5 ± 0.83	18256
@NP	range 7-9	18269
@NP	8.5 ± 1.2 -LRB- range 7-10 -RRB-	18281
@NP	8.5	18281
@NP	± 1.2 -LRB- range 7-10 -RRB-	18285
@NP	± 1.2	18285
@NP	range 7-10	18292
@NP	the corresponding score in the control and medium-injected groups	18322
@NP	the corresponding score	18322
@NP	the control and medium-injected groups	18349
@NP	the control	18349
@NP	medium-injected groups	18365
@NP	0.4 ± 0.53 -LRB- range 0-1 -RRB- and 0.66 ± 0.57 -LRB- range 0-1 -RRB-	18393
@NP	0.4 ± 0.53 -LRB- range 0-1 -RRB-	18393
@NP	0.4	18393
@NP	± 0.53 -LRB- range 0-1 -RRB-	18397
@NP	± 0.53	18397
@NP	range 0-1	18405
@NP	0.66 ± 0.57 -LRB- range 0-1 -RRB-	18420
@NP	0.66	18420
@NP	± 0.57 -LRB- range 0-1 -RRB-	18425
@NP	± 0.57	18425
@NP	range 0-1	18433
@NP	There	18445
@NP	no significant difference	18455
@NP	transplanted groups four weeks after transplantation	18489
@NP	transplanted groups	18489
@NP	four weeks	18509
@NP	transplantation	18526
@NP	Histological evaluation .	18543
@NP	Longitudinal sections of the injured animals	18568
@NP	Longitudinal sections	18568
@NP	the injured animals	18593
@NP	edema , inflammation and loss of normal tissue architecture	18620
@NP	edema , inflammation and loss	18620
@NP	normal tissue architecture	18652
@NP	the site of injury	18683
@NP	the site	18683
@NP	injury	18695
@NP	several cavities	18703
@NP	portions of the gray and white matters , surrounded by scar tissue	18749
@NP	portions	18749
@NP	the gray and white matters , surrounded by scar tissue	18761
@NP	the gray and white matters	18761
@NP	scar tissue	18803
@NP	this study	18819
@NP	axonal damage and gliosis	18831
@NP	axonal damage	18831
@NP	gliosis	18849
@NP	The extent of tissue damage	18871
@NP	The extent	18871
@NP	tissue damage	18885
@NP	the control and medium-injected groups	18918
@NP	the control	18918
@NP	medium-injected groups	18934
@NP	other groups -LRB- Fig 3-6 -RRB-	18962
@NP	other groups	18962
@NP	Fig 3-6	18976
@NP	Spinal tissue sparing	18986
@NP	the damaged area -LRB- including degenerate tissue and transplanted cells -RRB-	19028
@NP	the damaged area	19028
@NP	degenerate tissue and transplanted cells	19056
@NP	degenerate tissue	19056
@NP	transplanted cells	19078
@NP	spinal cord segment	19101
@NP	the control -LRB- 27.95 ± 3.52 -RRB-	19125
@NP	the control	19125
@NP	27.95 ± 3.52	19138
@NP	27.95 ±	19138
@NP	3.52	19146
@NP	medium-injected groups -LRB- 29.33 ± 4.04 -RRB- of the spinal cord	19156
@NP	medium-injected groups -LRB- 29.33 ± 4.04 -RRB-	19156
@NP	medium-injected groups	19156
@NP	29.33 ± 4.04	19180
@NP	29.33 ±	19180
@NP	4.04	19188
@NP	the spinal cord	19197
@NP	the segment examined	19214
@NP	the segment	19214
@NP	contrast	19250
@NP	significantly more spinal tissue -LRB- P < 0.001 -RRB-	19260
@NP	significantly more spinal tissue	19260
@NP	P < 0.001	19294
@NP	P	19294
@NP	< 0.001	19295
@NP	<	19295
@NP	0.001	19296
@NP	OEC -LRB- 63.95 ± 17.09 -RRB-	19317
@NP	OEC	19317
@NP	63.95 ± 17.09	19322
@NP	63.95 ±	19322
@NP	17.09	19330
@NP	ESMN -LRB- 70.93 ± 5.62 -RRB-	19338
@NP	ESMN	19338
@NP	70.93 ± 5.62	19344
@NP	70.93 ±	19344
@NP	5.62	19352
@NP	OEC + ESMN -LRB- 82.07 ± 7.83 -RRB- groups -LRB- Fig. 2B -RRB-	19362
@NP	OEC + ESMN -LRB- 82.07 ± 7.83 -RRB- groups	19362
@NP	OEC	19362
@NP	ESMN -LRB- 82.07 ± 7.83 -RRB- groups	19368
@NP	ESMN -LRB- 82.07 ± 7.83 -RRB-	19368
@NP	ESMN	19368
@NP	82.07 ± 7.83	19374
@NP	82.07 ±	19374
@NP	7.83	19382
@NP	groups	19388
@NP	Fig. 2B	19396
@NP	No significant differences in percentage of spared tissue	19406
@NP	No significant differences	19406
@NP	percentage of spared tissue	19436
@NP	percentage	19436
@NP	spared tissue	19450
@NP	control and medium-injected groups or OEC and ESMN groups	19483
@NP	control and medium-injected groups	19483
@NP	OEC and ESMN groups	19521
@NP	The OEC + ESMN group	19542
@NP	The OEC	19542
@NP	ESMN group	19552
@NP	a significantly greater percentage	19567
@NP	spared tissue than other groups -LRB- P < 0.05 -RRB-	19605
@NP	spared tissue	19605
@NP	other groups -LRB- P < 0.05 -RRB-	19624
@NP	other groups	19624
@NP	P < 0.05	19638
@NP	P	19638
@NP	< 0.05	19639
@NP	<	19639
@NP	0.05	19640
@NP	The ESMN group	19647
@NP	a greater percentage of myelinated area	19666
@NP	a greater percentage	19666
@NP	myelinated area	19690
@NP	control and medium-injected groups	19711
@NP	there	19751
@NP	no significant difference	19761
@NP	The percentage of myelinated area	19788
@NP	The percentage	19788
@NP	myelinated area	19806
@NP	OEC group than control , medium-injected and ESMN groups	19837
@NP	OEC group	19837
@NP	control , medium-injected and ESMN groups	19852
@NP	P < 0.05	19894
@NP	P	19894
@NP	< 0.05	19895
@NP	<	19895
@NP	0.05	19896
@NP	The OEC + ESMN group	19903
@NP	The OEC	19903
@NP	ESMN group	19913
@NP	a significantly greater percentage of myelinated area	19928
@NP	a significantly greater percentage	19928
@NP	myelinated area	19966
@NP	other groups -LRB- P < 0.05 -RRB- -LRB- Fig. 2B -RRB-	19987
@NP	other groups -LRB- P < 0.05 -RRB-	19987
@NP	other groups	19987
@NP	P < 0.05	20001
@NP	P	20001
@NP	< 0.05	20002
@NP	<	20002
@NP	0.05	20003
@NP	Fig. 2B	20010
@NP	cell counts	20031
@NP	we	20044
@NP	the number	20055
@NP	transplanted cells	20069
@NP	the longitudinal sections	20091
@NP	Hoechst-labeled cells	20120
@NP	Figs. 4A and 6B-D	20143
@NP	Figs. 4A	20143
@NP	6B-D	20156
@NP	GFPpositive	20166
@NP	Figs. 5A and 6A , 6C and 6D	20179
@NP	Figs. 5A	20179
@NP	6A , 6C and 6D	20192
@NP	We	20208
@NP	transplant GFP-positive and Hoechst-labeled cells	20230
@NP	the cavity	20287
@NP	tissue of the spinal cord	20309
@NP	tissue	20309
@NP	the spinal cord	20319
@NP	OEC and OEC + ESMN groups	20339
@NP	OEC	20339
@NP	OEC + ESMN groups	20347
@NP	many of the OEC	20366
@NP	many	20366
@NP	the OEC	20374
@NP	the cystic cavity	20414
@NP	the average numbers of cells	20437
@NP	the average numbers	20437
@NP	cells	20460
@NP	28524 ± 7287	20471
@NP	OEC and 26702 ± 12120 in OEC + ESMN groups	20487
@NP	OEC	20487
@NP	26702 ± 12120 in OEC + ESMN groups	20495
@NP	26702 ± 12120	20495
@NP	OEC + ESMN groups	20512
@NP	OEC	20512
@NP	ESMN groups	20518
@NP	ESMN and OEC + ESMN groups	20534
@NP	ESMN	20534
@NP	OEC + ESMN groups	20543
@NP	the numbers of GFP-positive cells	20562
@NP	the numbers	20562
@NP	GFP-positive cells	20577
@NP	5348 ± 2125 and 9362 ± 2783 , respectively -LRB- Fig. 2C -RRB-	20601
@NP	5348 ± 2125 and 9362 ± 2783 , respectively	20601
@NP	5348 ± 2125 and 9362 ± 2783	20601
@NP	5348	20601
@NP	± 2125 and 9362 ± 2783	20606
@NP	Fig. 2C	20644
@NP	There	20654
@NP	a significant difference	20664
@NP	cell number in OEC and ESMN groups -LRB- P < 0.001 -RRB-	20697
@NP	cell number	20697
@NP	OEC and ESMN groups -LRB- P < 0.001 -RRB-	20712
@NP	OEC and ESMN groups	20712
@NP	P < 0.001	20733
@NP	P	20733
@NP	< 0.001	20734
@NP	<	20734
@NP	0.001	20735
@NP	The Hoechst-labeled cells in OEC and OEC + ESMN	20743
@NP	The Hoechst-labeled cells	20743
@NP	OEC and OEC + ESMN	20772
@NP	OEC and OEC	20772
@NP	ESMN	20786
@NP	P > 0.05	20825
@NP	P	20825
@NP	> 0.05	20826
@NP	>	20826
@NP	0.05	20827
@NP	The numbers of GFP-positive cells in OEC + ESMN	20834
@NP	The numbers	20834
@NP	GFP-positive cells in OEC + ESMN	20849
@NP	GFP-positive cells	20849
@NP	OEC + ESMN	20871
@NP	OEC	20871
@NP	ESMN	20877
@NP	those of ESMN group -LRB- P < 0.05 -RRB-	20913
@NP	those	20913
@NP	ESMN group -LRB- P < 0.05 -RRB-	20922
@NP	ESMN group	20922
@NP	P < 0.05	20934
@NP	P	20934
@NP	< 0.05	20935
@NP	<	20935
@NP	0.05	20936
@NP	DISCUSSION Most SCI research	20944
@NP	DISCUSSION	20944
@NP	Most SCI research	20955
@NP	restoration	20984
@NP	white matter	20999
@NP	tracts -LRB- regeneration -RRB-	21017
@NP	tracts	21017
@NP	regeneration	21025
@NP	cellular replacement -LRB- neuronal or oligodendrocyte -RRB-	21043
@NP	cellular replacement	21043
@NP	neuronal or oligodendrocyte	21065
@NP	neuronal	21065
@NP	oligodendrocyte	21077
@NP	The most frequently used cell for white matter regeneration	21095
@NP	The most frequently used cell	21095
@NP	white matter regeneration	21129
@NP	OEC	21158
@NP	The results of this study	21163
@NP	The results	21163
@NP	this study	21178
@NP	OEC	21207
@NP	histological and functional recovery	21219
@NP	transplantation	21262
@NP	OEC group	21282
@NP	the sparing and myelination of spinal tissue	21293
@NP	the sparing and myelination	21293
@NP	spinal tissue	21324
@NP	cavity formation	21352
@NP	The mean BBB score in OEC group	21380
@NP	The mean BBB score	21380
@NP	OEC group	21402
@NP	control and medium-injected groups	21428
@NP	Several studies	21464
@NP	OEC transplantation	21500
@NP	promise	21526
@NP	a potential therapy for SCI	21537
@NP	a potential therapy	21537
@NP	SCI	21561
@NP	other studies	21575
@NP	OEC	21609
@NP	-LSB- 21 , 22 -RSB-	21642
@NP	Comparison of studies	21652
@NP	Comparison	21652
@NP	studies	21666
@NP	a multitude of approaches	21695
@NP	a multitude	21695
@NP	approaches	21710
@NP	different research groups	21724
@NP	example	21755
@NP	the various purification strategies and criteria used for defining OEC	21764
@NP	the various purification strategies and criteria	21764
@NP	OEC	21831
@NP	5 -RSB-	21836
@NP	the most successful experiments	21843
@NP	adult rats	21876
@NP	OEC transplants	21901
@NP	ability and sensorimotor reflexes	21936
@NP	complete spinal cord transaction -LSB- 23 -RSB- ,	21976
@NP	complete spinal cord transaction	21976
@NP	23 -RSB-	22010
@NP	respiratory function	22025
@NP	cervical hemisection -LSB- 24 -RSB- and bladder control	22052
@NP	cervical hemisection	22052
@NP	24 -RSB-	22074
@NP	bladder control	22082
@NP	lumbosacral dorsal root transaction -LSB- 25 -RSB-	22104
@NP	lumbosacral dorsal root transaction	22104
@NP	25 -RSB-	22141
@NP	This functional recovery	22146
@NP	anatomical and activity-based regeneration	22187
@NP	the associated axon tracts , including long distance regrowth of some axons	22233
@NP	the associated axon tracts	22233
@NP	long distance regrowth of some axons	22271
@NP	long distance regrowth	22271
@NP	some axons	22297
@NP	-LSB- 5 , 6 , 23 , 25 , 26 -RSB-	22308
@NP	Improvement of BBB score in previous	22328
@NP	Improvement	22328
@NP	BBB score in previous	22343
@NP	BBB score	22343
@NP	previous	22356
@NP	present research	22380
@NP	OEC	22409
@NP	profound effects	22417
@NP	corticospinal and other tracts involved in rat hindlimb movement	22437
@NP	corticospinal and other tracts	22437
@NP	rat hindlimb movement	22480
@NP	The effects of OEC on SCI	22503
@NP	The effects	22503
@NP	OEC on SCI	22518
@NP	OEC	22518
@NP	SCI	22525
@NP	nature of this cell	22540
@NP	nature	22540
@NP	this cell	22550
@NP	OEC	22561
@NP	several molecules	22573
@NP	axonal growth including NGF , BDNF , GDNF , and NT-4 / 5 -LSB- 5 , 6 -RSB-	22617
@NP	axonal growth	22617
@NP	NGF , BDNF , GDNF , and NT-4 / 5 -LSB- 5 , 6 -RSB-	22641
@NP	NGF	22641
@NP	BDNF	22646
@NP	GDNF	22652
@NP	NT-4 / 5 -LSB- 5 , 6 -RSB-	22662
@NP	NT-4	22662
@NP	5 -LSB- 5 , 6	22667
@NP	5	22667
@NP	-LSB- 5 , 6	22669
@NP	Reports	22677
@NP	OEC	22700
@NP	axonal regeneration	22744
@NP	a transplant	22780
@NP	it	22810
@NP	the white matter tracts of the host spinal cord	22818
@NP	the white matter tracts	22818
@NP	the host spinal cord	22845
@NP	Such regeneration	22867
@NP	several fiber types	22902
@NP	corticospinal , dorsal column and monoaminergic fibers -LSB- 6 -RSB-	22932
@NP	corticospinal	22932
@NP	dorsal column	22947
@NP	monoaminergic fibers -LSB- 6 -RSB-	22965
@NP	monoaminergic fibers	22965
@NP	6 -RSB-	22987
@NP	The increase in tissue sparing in the present study	22991
@NP	The increase	22991
@NP	tissue sparing in the present study	23007
@NP	tissue sparing	23007
@NP	the present study	23025
@NP	the promotion of axonal regeneration and extracellular matrix production	23059
@NP	the promotion	23059
@NP	axonal regeneration and extracellular matrix production	23076
@NP	axonal regeneration	23076
@NP	extracellular matrix production	23100
@NP	OEC transplantation	23138
@NP	Improvement of BBB	23159
@NP	Improvement	23159
@NP	BBB	23174
@NP	regeneration of axons	23199
@NP	regeneration	23199
@NP	axons	23215
@NP	establishment of new synaptic connections	23239
@NP	establishment	23239
@NP	new synaptic connections	23256
@NP	myelin sheath	23295
@NP	efficient propagation of action potentials	23319
@NP	efficient propagation	23319
@NP	action potentials	23344
@NP	OEC transplanted from rats into demyelinating lesions in the rat spinal cord	23363
@NP	OEC	23363
@NP	rats	23385
@NP	lesions	23409
@NP	the rat spinal cord	23420
@NP	remyelination of axons	23449
@NP	remyelination	23449
@NP	axons	23466
@NP	impulse conduction	23485
@NP	-LSB- 7 , 27 , 28 -RSB-	23504
@NP	Sasaki et al. -LSB- 29 -RSB-	23517
@NP	Sasaki et al. -LSB-	23517
@NP	transplantation of OEC expressing green fluorescent protein	23548
@NP	transplantation	23548
@NP	OEC expressing green fluorescent protein	23567
@NP	OEC	23567
@NP	green fluorescent protein	23582
@NP	transplanted cells	23623
@NP	about 50 % of the peripheral-type myelin around regenerating axons	23654
@NP	about 50 %	23654
@NP	the peripheral-type myelin around regenerating axons	23667
@NP	the peripheral-type myelin	23667
@NP	regenerating axons	23701
@NP	the remainder	23727
@NP	Schwann cells	23760
@NP	the transplant -LSB- 29 -RSB-	23787
@NP	the transplant	23787
@NP	29 -RSB-	23803
@NP	SCI	23814
@NP	most of the affected cells	23819
@NP	most	23819
@NP	the affected cells	23827
@NP	12 hours	23857
@NP	a delayed phase of cell death	23876
@NP	a delayed phase	23876
@NP	cell death	23895
@NP	several days or weeks	23919
@NP	Cell death	23942
@NP	the gray matter of the cord first	23963
@NP	the gray matter	23963
@NP	the cord first	23982
@NP	the cord	23982
@NP	the bodies of nerve cells	24004
@NP	the bodies	24004
@NP	nerve cells	24018
@NP	30 -RSB-	24038
@NP	we	24054
@NP	ES cells	24077
@NP	replacement of dead cells	24090
@NP	replacement	24090
@NP	dead cells	24105
@NP	the present study	24120
@NP	we	24139
@NP	ES cells	24152
@NP	a motor neuron fate	24164
@NP	transplantation	24191
@NP	the expression of motor neuron progenitor , motor neuron and interneuron markers	24221
@NP	the expression	24221
@NP	motor neuron progenitor , motor neuron and interneuron markers	24239
@NP	transplantation	24308
@NP	The result of this study	24325
@NP	The result	24325
@NP	this study	24339
@NP	the motor neuron progenitor markers -LRB- Pax6 , Nkx6 .1 and olig2 -RRB-	24362
@NP	the motor neuron progenitor markers	24362
@NP	Pax6 , Nkx6 .1 and olig2	24399
@NP	Pax6	24399
@NP	Nkx6 .1 and olig2	24405
@NP	ventral motor neuron markers -LRB- HB9 , Isl1and Isl2 -RRB-	24427
@NP	ventral motor neuron markers	24427
@NP	HB9 , Isl1and Isl2	24457
@NP	HB9	24457
@NP	Isl1and Isl2	24462
@NP	Our results	24492
@NP	interneuron markers Lim1 and Lim2	24518
@NP	interneuron markers	24518
@NP	Lim1 and Lim2	24538
@NP	cells	24585
@NP	This	24592
@NP	accordance with the results of previous researchers -LSB- 10 -RSB-	24603
@NP	accordance	24603
@NP	the results of previous researchers -LSB- 10 -RSB-	24619
@NP	the results	24619
@NP	previous researchers -LSB- 10 -RSB-	24634
@NP	previous researchers	24634
@NP	10 -RSB-	24656
@NP	the presence of RA	24664
@NP	the presence	24664
@NP	RA	24680
@NP	ES cells	24684
@NP	class I neural gene like Pax6 , irx3 , dbx1 and Pax7 in high levels	24701
@NP	class I neural gene	24701
@NP	class I	24701
@NP	Pax6 , irx3 , dbx1 and Pax7	24726
@NP	high levels	24755
@NP	class II like Nkx6 .1 and Olig2	24771
@NP	class II	24771
@NP	Nkx6 .1 and Olig2	24785
@NP	low levels	24805
@NP	This profile of transcription factor expression	24817
@NP	This profile	24817
@NP	transcription factor expression	24833
@NP	interneuron progenitors -LSB- 31 -RSB-	24886
@NP	interneuron progenitors	24886
@NP	31 -RSB-	24911
@NP	The induction of motor neuron progenitors	24916
@NP	The induction	24916
@NP	motor neuron progenitors	24933
@NP	Shh activity -LSB- 10 -RSB-	24969
@NP	Shh activity	24969
@NP	10 -RSB-	24983
@NP	Shh	24995
@NP	EB	25002
@NP	class II genes	25015
@NP	class	25015
@NP	II genes	25021
@NP	the expression of Pax7	25042
@NP	the expression	25042
@NP	Pax7	25060
@NP	transplantation of differentiated ES cells	25072
@NP	transplantation	25072
@NP	ES cells	25106
@NP	the tissue sparing and BBB	25116
@NP	the tissue sparing	25116
@NP	BBB	25139
@NP	cavity ratio	25163
@NP	to control and medium-injected groups	25195
@NP	medium-injected groups	25210
@NP	There	25234
@NP	no significant difference	25244
@NP	tissue sparing , cavity ratio and BBB score	25278
@NP	tissue sparing	25278
@NP	cavity ratio	25294
@NP	BBB score	25311
@NP	OEC and ESMN groups	25324
@NP	myelin ratio in OEC group	25348
@NP	myelin ratio	25348
@NP	OEC group	25364
@NP	Our results	25386
@NP	many ESMN	25410
@NP	transplantation	25430
@NP	some of them	25451
@NP	some	25451
@NP	them	25459
@NP	the cavity	25469
@NP	spinal cord and established neuronal network	25496
@NP	spinal cord	25496
@NP	established neuronal network	25512
@NP	McDonald and Howard -LSB- 32 -RSB-	25542
@NP	McDonald and Howard	25542
@NP	32 -RSB-	25563
@NP	the same result	25574
@NP	transplantation of ES derived neuronal cells	25596
@NP	transplantation	25596
@NP	ES derived neuronal cells	25615
@NP	ES	25615
@NP	neuronal cells	25626
@NP	Other researchers	25642
@NP	ESMN for brain damage	25665
@NP	ESMN	25665
@NP	brain damage	25674
@NP	the grafted cells	25702
@NP	the implantation site	25747
@NP	substantial migration	25789
@NP	the damaged lesion in a directed manner up to the cortical region	25829
@NP	the damaged lesion	25829
@NP	a directed manner up to the cortical region	25851
@NP	a directed manner	25851
@NP	the cortical region	25875
@NP	They	25896
@NP	the transplanted neurons	25916
@NP	the recipient neurons	25957
@NP	a neural network -LSB- 33 -RSB-	25987
@NP	a neural network	25987
@NP	33 -RSB-	26005
@NP	Partial recovery	26010
@NP	paralysis after transplantation of mES cells treated with Shh and RA	26032
@NP	paralysis	26032
@NP	transplantation of mES cells treated with Shh and RA	26048
@NP	transplantation	26048
@NP	mES cells treated with Shh and RA	26067
@NP	mES cells	26067
@NP	Shh and RA	26090
@NP	2 -RSB-	26115
@NP	other researchers	26128
@NP	transplantation	26157
@NP	apoptosis	26176
@NP	cells derived from KD3 line into the injured spinal cord	26211
@NP	cells	26211
@NP	KD3 line	26230
@NP	the injured spinal cord	26244
@NP	locomotor recovery	26284
@NP	tumor-like growth	26314
@NP	cells , accompanied by increased debilitation , morbidity and mortality	26335
@NP	cells	26335
@NP	increased debilitation , morbidity and mortality	26357
@NP	Our results	26406
@NP	increase in tissue sparing	26433
@NP	increase	26433
@NP	tissue sparing	26445
@NP	1 -RRB- transplanted motor	26477
@NP	neuron and other cell types	26499
@NP	cell mixture	26530
@NP	neural network	26557
@NP	endogenous neural progenitors	26576
@NP	3 -RRB- extracellular matrix produced by progenitors	26610
@NP	extracellular matrix	26613
@NP	progenitors	26646
@NP	ES cells -LSB- 30 -RSB-	26671
@NP	ES cells	26671
@NP	30 -RSB-	26681
@NP	Previous researchers	26686
@NP	neural progenitors that are endogenous to the central nervous system	26726
@NP	neural progenitors	26726
@NP	the central nervous system	26768
@NP	progenitors derived from ES cells	26796
@NP	progenitors	26796
@NP	ES cells	26821
@NP	considerable quantities	26838
@NP	extracellular matrix like laminin and fibronectin	26865
@NP	extracellular matrix	26865
@NP	laminin and fibronectin	26891
@NP	30 -RSB-	26916
@NP	The myelin ratio	26921
@NP	the ESMN group	26953
@NP	control and medium-injected groups	26982
@NP	there	27022
@NP	no significant difference	27032
@NP	The low levels of myelination	27059
@NP	The low levels	27059
@NP	myelination	27077
@NP	small number of oligodendrocyte differentiated by action of RA on ES cells	27108
@NP	small number	27108
@NP	oligodendrocyte differentiated by action of RA on ES cells	27124
@NP	oligodendrocyte	27124
@NP	action of RA	27158
@NP	action	27158
@NP	RA	27168
@NP	ES cells	27174
@NP	The previous reports	27184
@NP	ES	27222
@NP	oligodendrocytes	27237
@NP	injured spinal cord -LSB- 30 -RSB-	27270
@NP	injured spinal cord	27270
@NP	30 -RSB-	27291
@NP	We	27296
@NP	the mean of Hoechst-labeled cells in OEC group	27315
@NP	the mean	27315
@NP	Hoechst-labeled cells in OEC group	27327
@NP	Hoechst-labeled cells	27327
@NP	OEC group	27352
@NP	GFP-positive cells in ESMN group	27393
@NP	GFP-positive cells	27393
@NP	ESMN group	27415
@NP	The reduction of GFP-positive cells	27427
@NP	The reduction	27427
@NP	GFP-positive cells	27444
@NP	the injured environment and rejection	27479
@NP	the injured environment	27479
@NP	rejection	27507
@NP	transplantation	27523
@NP	Many ESMN	27540
@NP	transplantation	27560
@NP	some of them	27581
@NP	some	27581
@NP	them	27589
@NP	neuronal network	27619
@NP	Previous researchers	27637
@NP	only few of ESMN	27673
@NP	only few	27673
@NP	ESMN	27685
@NP	axons	27699
@NP	the peripheral nervous system	27710
@NP	the survival rate of these cells in spinal cord	27749
@NP	the survival rate	27749
@NP	these cells in spinal cord	27770
@NP	these cells	27770
@NP	spinal cord	27785
@NP	-LSB- 10 , 11 -RSB-	27811
@NP	Shukla et al. -LSB- 34 -RSB-	27821
@NP	Shukla et al. -LSB-	27821
@NP	transplantation	27852
@NP	neural stem cell	27871
@NP	the mesencephalic region of brain	27894
@NP	the mesencephalic region	27894
@NP	brain	27922
@NP	dopamine neurons	27937
@NP	low survival of cells , limited host-graft interaction and poor axonal outgrowth	27973
@NP	low survival	27973
@NP	cells , limited host-graft interaction and poor axonal outgrowth	27989
@NP	cells	27989
@NP	limited host-graft interaction	27996
@NP	poor axonal outgrowth	28031
@NP	They	28054
@NP	the co-transplantation	28069
@NP	OEC and neural stem cell	28095
@NP	the mesencephalic region of brain	28126
@NP	the mesencephalic region	28126
@NP	brain	28154
@NP	dopamine neuron	28169
@NP	the presence of OEC	28207
@NP	the presence	28207
@NP	OEC	28223
@NP	survival of neural stem	28251
@NP	survival	28251
@NP	neural stem	28263
@NP	cell-derived dopamine neurons	28275
@NP	axonal fiber outgrowth and restitution	28306
@NP	motor function recovery	28348
@NP	the co-transplanted group	28388
@NP	the present study	28418
@NP	we	28437
@NP	the effect of cotransplantation of ESMN and OEC	28450
@NP	the effect	28450
@NP	cotransplantation of ESMN and OEC	28464
@NP	cotransplantation	28464
@NP	ESMN and OEC	28485
@NP	We	28499
@NP	the lost neurons	28520
@NP	ESMN	28571
@NP	the OEC	28583
@NP	the survival of transplanted ESMN	28606
@NP	the survival	28606
@NP	transplanted ESMN	28622
@NP	NTF and cell adhesion molecules	28657
@NP	The results	28690
@NP	tissue sparing and myelin ratio	28714
@NP	tissue sparing	28714
@NP	myelin ratio	28733
@NP	other groups	28763
@NP	This finding	28777
@NP	the synergistic effects of two cell types	28806
@NP	the synergistic effects	28806
@NP	two cell types	28833
@NP	spinal cord	28864
@NP	The survival rate of GFPpositive cells in co-transplanted group	28877
@NP	The survival rate	28877
@NP	GFPpositive cells in co-transplanted group	28898
@NP	GFPpositive cells	28898
@NP	co-transplanted group	28919
@NP	ESMN group	28960
@NP	This	28972
@NP	the first report of positive effects of OEC on survival rate of ESMN	28980
@NP	the first report	28980
@NP	positive effects of OEC on survival rate of ESMN	29000
@NP	positive effects	29000
@NP	OEC on survival rate of ESMN	29020
@NP	OEC	29020
@NP	survival rate of ESMN	29027
@NP	survival rate	29027
@NP	ESMN	29044
@NP	This	29050
@NP	GFP-positive cells in the spinal cord	29064
@NP	GFP-positive cells	29064
@NP	the spinal cord	29086
@NP	the existence	29111
@NP	functional graft at transplantation site	29128
@NP	functional graft	29128
@NP	transplantation site	29148
@NP	the higher survival of ESMN neurons in graft itself	29191
@NP	the higher survival	29191
@NP	ESMN neurons in graft itself	29214
@NP	ESMN neurons	29214
@NP	graft	29230
@NP	possible resprouting of intrinsic neurons in response	29254
@NP	possible resprouting	29254
@NP	intrinsic neurons in response	29278
@NP	intrinsic neurons	29278
@NP	response	29299
@NP	various NTF including NGF , secreted by OEC	29311
@NP	various NTF	29311
@NP	NGF , secreted by OEC	29333
@NP	NGF	29333
@NP	OEC	29350
@NP	contact-mediated support of OEC to residual axonal fibers	29365
@NP	contact-mediated support	29365
@NP	OEC to residual axonal fibers	29393
@NP	OEC	29393
@NP	residual axonal fibers	29400
@NP	NGF	29430
@NP	dual activity	29439
@NP	NTF support	29466
@NP	properties of antioxidant -LSB-	29489
@NP	properties	29489
@NP	antioxidant -LSB-	29503
@NP	35 -RSB- , anti-apoptotic -LSB- 36 -RSB- , and neurorescue activity	29516
@NP	35 -RSB-	29516
@NP	anti-apoptotic -LSB- 36 -RSB- , and neurorescue activity	29521
@NP	anti-apoptotic -LSB- 36 -RSB-	29521
@NP	anti-apoptotic -LSB-	29521
@NP	neurorescue activity	29546
@NP	OEC	29568
@NP	olfactory bulb , release NTFs such as NGF	29585
@NP	olfactory bulb	29585
@NP	release NTFs such as NGF	29601
@NP	release NTFs	29601
@NP	NGF	29622
@NP	GDNF , BDNF , NT-4	29627
@NP	GDNF , BDNF ,	29627
@NP	NT-4	29639
@NP	5 , CNTF and FGF2 -LSB- 5 , 6 -RSB-	29644
@NP	5	29644
@NP	CNTF and FGF2	29647
@NP	5	29662
@NP	6 -RSB-	29665
@NP	NGF	29669
@NP	the number of dopamine neurons in lesioned nigral region and graft	29693
@NP	the number	29693
@NP	dopamine neurons in lesioned nigral region and graft	29707
@NP	dopamine neurons	29707
@NP	lesioned nigral region and graft	29727
@NP	37 -RSB- , increase synapse formation	29761
@NP	37 -RSB-	29761
@NP	increase synapse formation	29766
@NP	neuronal path finding	29808
@NP	the expression	29843
@NP	cell adhesion molecules	29861
@NP	nerve cells	29888
@NP	guiding axons in establishing connectivity with host cells -LSB- 38 -RSB-	29905
@NP	guiding axons	29905
@NP	connectivity	29935
@NP	host cells -LSB- 38 -RSB-	29953
@NP	host cells	29953
@NP	38 -RSB-	29965
@NP	We	29970
@NP	increased survival of transplanted cells in the co-transplanted group	29990
@NP	increased survival	29990
@NP	transplanted cells in the co-transplanted group	30012
@NP	transplanted cells	30012
@NP	the co-transplanted group	30034
@NP	the expression	30085
@NP	neural cell adhesion molecules , L1 and growth associated proteins	30103
@NP	neural cell adhesion molecules	30103
@NP	L1	30135
@NP	growth associated proteins	30142
@NP	OEC	30172
@NP	synapse formation and neuronal path finding	30193
@NP	synapse formation	30193
@NP	neuronal path finding	30215
@NP	guiding axons in making connections -LSB- 38 -RSB-	30240
@NP	guiding axons	30240
@NP	connections -LSB- 38 -RSB-	30264
@NP	connections	30264
@NP	38 -RSB-	30277
@NP	The BBB score	30282
@NP	ESMN and OEC groups	30321
@NP	The authors	30342
@NP	transplanted neurons	30367
@NP	more functional synaptic connections	30409
@NP	the length of study	30449
@NP	the length	30449
@NP	study	30463
@NP	hindlimb improvement	30491
@NP	Therapeutic use of stem cells to regenerate motor neurons in the spinal cord	30513
@NP	Therapeutic use	30513
@NP	stem cells	30532
@NP	motor neurons	30557
@NP	the spinal cord	30574
@NP	a method	30599
@NP	cell survival	30625
@NP	extended periods of time	30643
@NP	extended periods	30643
@NP	time	30663
@NP	axons	30682
@NP	the white matter toward muscle targets	30696
@NP	the white matter	30696
@NP	muscle targets	30720
@NP	We	30736
@NP	the cotransplantation of ESMN and OEC into an injured spinal cord	30755
@NP	the cotransplantation	30755
@NP	ESMN and OEC into an injured spinal cord	30780
@NP	ESMN and OEC	30780
@NP	an injured spinal cord	30798
@NP	a synergistic effect	30826
@NP	neural regeneration , ESMN survival and functional recovery	30858
@NP	neural regeneration	30858
@NP	ESMN survival	30879
@NP	functional recovery	30897
@NP	we	30929
@NP	a new strategy	30944
@NP	treatment of SCI	30963
@NP	treatment	30963
@NP	SCI	30976
@NP	co-transplantation of ESMN and OEC	30983
@NP	co-transplantation	30983
@NP	ESMN and OEC	31005
@VP	has been attributed to axonal demyelination and neuronal death	208
@VP	been attributed to axonal demyelination and neuronal death	212
@VP	attributed to axonal demyelination and neuronal death	217
@VP	are both necessary for SCI repair	323
@VP	cultured from olfactory nerve rootlets and olfactory bulbs	534
@VP	was generated by exposing mouse ES cells to retinoic acid and sonic hedgehog	599
@VP	generated by exposing mouse ES cells to retinoic acid and sonic hedgehog	603
@VP	exposing mouse ES cells to retinoic acid and sonic hedgehog	616
@VP	were used to prepare SCI models in five groups	696
@VP	used to prepare SCI models in five groups	701
@VP	to prepare SCI models in five groups	706
@VP	prepare SCI models in five groups	709
@VP	was subjected to induce lesion without cell transplantation	778
@VP	subjected to induce lesion without cell transplantation	782
@VP	to induce lesion without cell transplantation	792
@VP	induce lesion without cell transplantation	795
@VP	were transplanted into the site of the lesion in other groups	859
@VP	transplanted into the site of the lesion in other groups	864
@VP	was 95 %	957
@VP	were expressed	1069
@VP	expressed	1074
@VP	was spared in OEC , ESMN and OEC	1162
@VP	spared in OEC , ESMN and OEC	1166
@VP	were significantly higher than ESMN group -LRB- P < 0.05 -RRB-	1377
@VP	was observed in rats in the transplanted groups	1482
@VP	observed in rats in the transplanted groups	1486
@VP	promoting neural regeneration , ESMN survival and partial functional recovery	1650
@VP	persist for the life of the patient	1800
@VP	can be applied to prevent or reduce disability	1923
@VP	be applied to prevent or reduce disability	1927
@VP	applied to prevent or reduce disability	1930
@VP	to prevent or reduce disability	1938
@VP	prevent or reduce disability	1941
@VP	to regenerate spinal cord	1999
@VP	regenerate spinal cord	2002
@VP	is cellular transplantation	2025
@VP	replace dead cells , remyelinate axons	2084
@VP	also create a favorable environment for axon regeneration	2126
@VP	associates with the olfactory nerve , surrounding the sensory axons	2388
@VP	surrounding the sensory axons	2425
@VP	made OEC a candidate for spinal cord repair -LSB- 7-9 -RSB-	2593
@VP	using stem cell-derived motor neurons -LSB- 10 , 11 -RSB-	2735
@VP	include replicating indefinitely without aging	2836
@VP	replicating indefinitely without aging	2844
@VP	giving rise to all different cell types in the body -LSB- 12 -RSB-	2898
@VP	deriving specific neuronal and glial subtypes from ES cells	3015
@VP	have been developed	3075
@VP	been developed	3080
@VP	developed	3085
@VP	arrest spinal motor neuron degeneration	3300
@VP	restore function to animals with SCI -LSB- 2 , 6 -RSB-	3344
@VP	engrafted into the spinal cord	3548
@VP	will not survive	3579
@VP	survive	3588
@VP	injured rats	3763
@VP	were obtained from the Razi Vaccine and Serum Research Institute , Karaj , Iran	3873
@VP	obtained from the Razi Vaccine and Serum Research Institute , Karaj , Iran	3878
@VP	were maintained on a 12 hour dark/light cycle at 20 °C	3964
@VP	maintained on a 12 hour dark/light cycle at 20 °C	3969
@VP	was proportioned ad libitum	4034
@VP	inducing SCI	4195
@VP	used 10 rats for OEC culture	4615
@VP	used Nash -LSB- 13 -RSB- methods with some modifications -LSB- 14 -RSB-	4692
@VP	anesthetized with overdose of ketamine and xylazine and killed by decapitation	4765
@VP	anesthetized with overdose of ketamine and xylazine	4765
@VP	killed by decapitation	4821
@VP	extending from the tip of the nose to the occipital bone of the skull	4883
@VP	were removed	4985
@VP	removed	4990
@VP	was divested of all meninges and blood vessels	5167
@VP	divested of all meninges and blood vessels	5171
@VP	were dissected and retained	5282
@VP	dissected and retained	5287
@VP	minced	5328
@VP	incubated within a solution of 0.25 % collagenase type IA and dispase	5339
@VP	was inactivated using HBSS	5632
@VP	inactivated using HBSS	5636
@VP	using HBSS	5648
@VP	centrifuged at 300 × g for 5 minutes	5691
@VP	containing 10 % fetal bovine serum -LRB- FBS , Sigma -RRB-	5795
@VP	containing 95 % air and 5 % CO2 for 18 hours	5989
@VP	attached to plate during this first incubation period	6083
@VP	were removed and plated in a second set of uncoated culture flasks	6172
@VP	removed and plated in a second set of uncoated culture flasks	6177
@VP	remained in the supernatant	6286
@VP	was used to seed a set of poly-L-lysine -LRB- Sigma -RRB- flasks	6332
@VP	used to seed a set of poly-L-lysine -LRB- Sigma -RRB- flasks	6336
@VP	seeding	6394
@VP	attached within 48 hours	6411
@VP	continued until appropriate cell number was achieved	6446
@VP	was achieved	6486
@VP	achieved	6490
@VP	were changed every 2 days	6513
@VP	changed every 2 days	6518
@VP	using feeder-free GFP-positive CGR8 mouse ES cells	6623
@VP	-LSB- 10 -RSB-	6724
@VP	were dissociated and cultured in DFK5 medium	7079
@VP	dissociated and cultured in DFK5 medium	7084
@VP	to form Embryoid Body -LRB- EB -RRB-	7457
@VP	form Embryoid Body -LRB- EB -RRB-	7460
@VP	were cultured for 4 days	7587
@VP	cultured for 4 days	7592
@VP	supplemented with 1 % N2 -LRB- Gibco , USA -RRB-	7699
@VP	were fixed by incubation in 4 % paraformaldehyde -LRB- Sigma , USA -RRB-	7893
@VP	fixed by incubation in 4 % paraformaldehyde -LRB- Sigma , USA -RRB-	7898
@VP	rinsed with PBS	7976
@VP	permeabilized with 0.1 % Triton X-100 -LRB- Sigma , USA -RRB- in PBS	7996
@VP	followed by incubation with primary antibodies at 4 °C overnight	8148
@VP	rinsed with PBS and incubated with a species-specific secondary antibody	8229
@VP	rinsed with PBS	8229
@VP	incubated with a species-specific secondary antibody	8249
@VP	were washed with three changes of PBS	8312
@VP	washed with three changes of PBS	8317
@VP	visualized by fluorescent microscope	8411
@VP	differentiated mouse ES cells	8784
@VP	was isolated from cells using the RNX plus kit -LRB- Cinnagen , Iran -RRB-	9068
@VP	isolated from cells using the RNX plus kit -LRB- Cinnagen , Iran -RRB-	9072
@VP	using the RNX plus kit -LRB- Cinnagen , Iran -RRB-	9092
@VP	performed at 94 °C for 1 minute	9289
@VP	followed by 30 cycles of 94 °C for 30 s	9321
@VP	Amplified DNA fragments were electrophoresed on 1.5 % agarose gel and the gels	9418
@VP	were electrophoresed on 1.5 % agarose gel and the gels	9442
@VP	electrophoresed on 1.5 % agarose gel and the gels	9447
@VP	stained with ethidium bromide -LRB- 10 μg/ml -RRB-	9501
@VP	photographed on a UV transilluminator -LRB- Uvidoc , UK -RRB-	9546
@VP	are listed in Table 1	9610
@VP	listed in Table 1	9614
@VP	was induced using Vanicky 's method -LSB- 15 -RSB-	9658
@VP	induced using Vanicky 's method -LSB- 15 -RSB-	9662
@VP	using Vanicky 's method -LSB- 15 -RSB-	9670
@VP	were removed	9874
@VP	removed	9879
@VP	was drilled in vertebral arch of T10	9920
@VP	drilled in vertebral arch of T10	9924
@VP	was inserted into the epidural space	10004
@VP	inserted into the epidural space	10008
@VP	advanced cranially so that the center of the balloon rested at T8-T9 level	10045
@VP	rested at T8-T9 level	10098
@VP	was rapidly inflated with 20 μl saline for 5 minutes	10133
@VP	inflated with 20 μl saline for 5 minutes	10145
@VP	removed	10196
@VP	sutured	10229
@VP	was performed two times per day	10366
@VP	performed two times per day	10370
@VP	were treated with suspension of cefazolin and of 12 mg/kg gentamicin	10424
@VP	treated with suspension of cefazolin and of 12 mg/kg gentamicin	10429
@VP	to stop self-mutilation	10566
@VP	stop self-mutilation	10569
@VP	labeling	10599
@VP	rinsed several times with DMEM without serum	10777
@VP	resuspended in the same medium	10823
@VP	transplanted into the spinal cord	10858
@VP	were performed 9 days after the injury -LSB- 17 -RSB-	10927
@VP	performed 9 days after the injury -LSB- 17 -RSB-	10932
@VP	received cyclosporine -LRB- 10 mg/kg , SC -RRB- on day 8 for immunosuppression	10989
@VP	continued for duration of survival -LSB- 18 -RSB-	11061
@VP	ESMN group by means of 5 μL Hamilton syringe	11269
@VP	was injected into the center of the syrinx at T9 level over a 5-minute period	11372
@VP	injected into the center of the syrinx at T9 level over a 5-minute period	11376
@VP	was sutured	11491
@VP	sutured	11495
@VP	received antibiotic	11512
@VP	using two independent observers -LSB- 19 -RSB-	11657
@VP	followed by 4 % paraformaldehyde and 2.5 % glutaraldehyde in PBS	11992
@VP	were dissected , postfixed and transferred to 10 % sucrose	12073
@VP	dissected , postfixed and transferred to 10 % sucrose	12078
@VP	dissected	12078
@VP	postfixed	12089
@VP	transferred to 10 % sucrose	12103
@VP	were embedded into TissueTek OCT compound	12141
@VP	embedded into TissueTek OCT compound	12146
@VP	were cut on a cryostat and mounted on Poly-LLysine coated slides	12225
@VP	cut on a cryostat and mounted on Poly-LLysine coated slides	12230
@VP	cut on a cryostat	12230
@VP	mounted on Poly-LLysine coated slides	12252
@VP	were captured by digital camera	12439
@VP	captured by digital camera	12444
@VP	were measured using image analysis software -LRB- Image J , NIH -RRB-	12516
@VP	measured using image analysis software -LRB- Image J , NIH -RRB-	12521
@VP	using image analysis software -LRB- Image J , NIH -RRB-	12530
@VP	To perform cell counts	12576
@VP	perform cell counts	12579
@VP	using fluorescent microscope	12752
@VP	were selected	12805
@VP	selected	12810
@VP	was performed on 50 slides in each animal	12838
@VP	performed on 50 slides in each animal	12842
@VP	was used to determine the spared tissue and myelinated area	12912
@VP	used to determine the spared tissue and myelinated area	12916
@VP	to determine the spared tissue and myelinated area	12921
@VP	determine the spared tissue and myelinated area	12924
@VP	were measured	13095
@VP	measured	13100
@VP	were summed per rat and corrected for the total number of sections	13141
@VP	summed per rat and corrected for the total number of sections	13146
@VP	summed per rat	13146
@VP	corrected for the total number of sections	13165
@VP	followed by Tukey 's post hoc test	13520
@VP	using non-parametric analysis	13696
@VP	followed by Mann - Whitney U test	13742
@VP	were compared with independent t-test	13877
@VP	compared with independent t-test	13882
@VP	was accepted at P < 0.05	13955
@VP	accepted at P < 0.05	13959
@VP	used for PCR amplification	14014
@VP	expressing p75	14083
@VP	emerging from aggregate	14140
@VP	treated	14451
@VP	received contusion injury on Day 0	14509
@VP	were made on Day 9	14557
@VP	made on Day 9	14562
@VP	receiving transplants	14598
@VP	were significantly different from control and medium-injected groups	14620
@VP	spared tissue and myelinated area in five groups	14708
@VP	show the cell counts	14889
@VP	was significantly larger than that in the ESMN group	14969
@VP	using Luxol fast blue -LRB- A and C -RRB- and silver nitrate -LRB- B and D -RRB-	15216
@VP	formed in the injured area -LRB- Stars -RRB-	15300
@VP	was not stained with Luxol fast blue	15360
@VP	stained with Luxol fast blue	15368
@VP	show damaged area	15405
@VP	produced myelin -LRB- B and C stained by Luxol fast blue , arrows -RRB-	15576
@VP	stained by Luxol fast blue , arrows	15601
@VP	survived in spinal cord and established neuronal network	15859
@VP	stained by Luxol fast blue	15978
@VP	stained by silver nitrate -LRB- C , arrows -RRB-	16024
@VP	is a receptor found on the external surface of the plasma membranes of OEC	16089
@VP	found on the external surface of the plasma membranes of OEC	16103
@VP	obtained	16215
@VP	were determined by counting the immunofluorescently labeled cell types	16224
@VP	determined by counting the immunofluorescently labeled cell types	16229
@VP	counting the immunofluorescently labeled cell types	16243
@VP	was 95 % -LRB- Fig. 1A -RRB-	16351
@VP	treated EB , many of aggregates	16436
@VP	gave off extensive outgrowth of neuritis	16467
@VP	forming a dense , tangled collection of neuritis -LRB- Fig. 1B -RRB-	16582
@VP	determine if the neuron-like cells and process contain neuronassociated proteins	16653
@VP	contain neuronassociated proteins	16700
@VP	To characterize expression of neuronal gene in differentiated ES cultures	16822
@VP	characterize expression of neuronal gene in differentiated ES cultures	16825
@VP	differentiated ES cultures	16869
@VP	were expressed	17094
@VP	expressed	17099
@VP	was higher than that of Nkx6 .1	17146
@VP	were expressed	17220
@VP	expressed	17225
@VP	was higher than that of Isl2	17267
@VP	were expressed	17333
@VP	expressed	17338
@VP	had a higher expression	17357
@VP	were expressed in low levels	17433
@VP	expressed in low levels	17438
@VP	were assessed and selected for transplantation	17618
@VP	assessed and selected for transplantation	17623
@VP	were that the animal must score 0-2 on day nine	17707
@VP	must score 0-2 on day nine	17728
@VP	score 0-2 on day nine	17733
@VP	were 7.33	18228
@VP	were 0.4 ± 0.53 -LRB- range 0-1 -RRB- and 0.66 ± 0.57 -LRB- range 0-1 -RRB-	18388
@VP	showed edema , inflammation and loss of normal tissue architecture	18613
@VP	disrupted portions of the gray and white matters , surrounded by scar tissue	18739
@VP	surrounded by scar tissue	18789
@VP	were visible	18857
@VP	examined	19226
@VP	was spared	19235
@VP	spared	19239
@VP	were found between control and medium-injected groups or OEC and ESMN groups	19464
@VP	found between control and medium-injected groups or OEC and ESMN groups	19469
@VP	was no significant difference	19757
@VP	To perform cell counts	20020
@VP	perform cell counts	20023
@VP	surviving transplant GFP-positive and Hoechst-labeled cells within the cavity	20220
@VP	spared tissue of the spinal cord	20302
@VP	were detected around and within the cystic cavity	20382
@VP	detected around and within the cystic cavity	20387
@VP	were 28524 ± 7287 in OEC and 26702 ± 12120 in OEC + ESMN groups	20466
@VP	were 5348 ± 2125 and 9362 ± 2783 , respectively -LRB- Fig. 2C -RRB-	20596
@VP	were not significantly different -LRB- P > 0.05 -RRB-	20791
@VP	were significantly higher than those of ESMN group -LRB- P < 0.05 -RRB-	20882
@VP	is OEC	21155
@VP	promote histological and functional recovery after transplantation	21211
@VP	increased	21338
@VP	decreased	21369
@VP	was higher than control and medium-injected groups	21412
@VP	have suggested that OEC may not always be beneficial -LSB- 21 , 22 -RSB-	21589
@VP	suggested that OEC may not always be beneficial -LSB- 21 , 22 -RSB-	21594
@VP	may not always be beneficial -LSB- 21 , 22 -RSB-	21613
@VP	be beneficial -LSB- 21 , 22 -RSB-	21628
@VP	is made difficult by a multitude of approaches by different research groups	21674
@VP	made difficult by a multitude of approaches by different research groups	21677
@VP	used for defining OEC	21813
@VP	defining OEC	21822
@VP	-LSB- 5 -RSB-	21835
@VP	researches	22365
@VP	involved in rat hindlimb movement	22468
@VP	are due to nature of this cell	22529
@VP	needs regeneration of axons	23193
@VP	also requires establishment of new synaptic connections	23225
@VP	attaining myelin sheath to enable efficient propagation of action potentials	23285
@VP	to enable efficient propagation of action potentials	23309
@VP	enable efficient propagation of action potentials	23312
@VP	transplanted from rats into demyelinating lesions in the rat spinal cord	23367
@VP	demyelinating lesions in the rat spinal cord	23395
@VP	promoted remyelination of axons	23440
@VP	restored impulse conduction -LSB- 7 , 27 , 28 -RSB-	23476
@VP	expressing green fluorescent protein	23571
@VP	is attributable to Schwann cells infiltrating the transplant -LSB- 29 -RSB-	23741
@VP	infiltrating the transplant -LSB- 29 -RSB-	23774
@VP	die within 12 hours	23846
@VP	persists for several days or weeks	23906
@VP	reside -LSB- 30 -RSB-	24030
@VP	used differentiated ES cells for replacement of dead cells	24057
@VP	differentiated ES cells for replacement of dead cells	24062
@VP	committed ES cells to a motor neuron fate before transplantation	24142
@VP	were expressed	24476
@VP	expressed	24481
@VP	were expressed in differentiated cells	24552
@VP	expressed in differentiated cells	24557
@VP	differentiated cells	24570
@VP	is in accordance with the results of previous researchers -LSB- 10 -RSB-	24597
@VP	is characteristic of interneuron progenitors -LSB- 31 -RSB-	24865
@VP	depends on Shh activity -LSB- 10 -RSB-	24958
@VP	Adding Shh to EB	24988
@VP	increases class II genes but reduces the expression of Pax7	25005
@VP	increases class II genes	25005
@VP	reduces the expression of Pax7	25034
@VP	differentiated ES cells	25091
@VP	score increased	25143
@VP	increased	25149
@VP	decreased compared to control and medium-injected groups	25176
@VP	to control	25195
@VP	control	25198
@VP	was higher	25374
@VP	showed that many ESMN die after transplantation	25398
@VP	die after transplantation	25420
@VP	fill the cavity and remained in spinal cord and established neuronal network	25464
@VP	fill the cavity	25464
@VP	remained in spinal cord and established neuronal network	25484
@VP	showed the same result after transplantation of ES derived neuronal cells	25567
@VP	derived neuronal cells	25618
@VP	used ESMN for brain damage	25660
@VP	remained close to the implantation site	25729
@VP	interacted with the recipient neurons to form a neural network -LSB- 33 -RSB-	25941
@VP	to form a neural network -LSB- 33 -RSB-	25979
@VP	form a neural network -LSB- 33 -RSB-	25982
@VP	treated with Shh and RA	26077
@VP	was reported -LSB- 2 -RSB-	26101
@VP	reported -LSB- 2 -RSB-	26105
@VP	differentiated cells derived from KD3 line into the injured spinal cord	26196
@VP	derived from KD3 line into the injured spinal cord	26217
@VP	did not improve locomotor recovery	26268
@VP	improve locomotor recovery	26276
@VP	accompanied by increased debilitation , morbidity and mortality	26342
@VP	derived from ES cells -LSB- 30 -RSB-	26658
@VP	are endogenous to the central nervous system	26750
@VP	derived from ES cells	26808
@VP	was greater in the ESMN group compared with control and medium-injected groups	26938
@VP	was no significant difference	27028
@VP	differentiated by action of RA on ES cells	27140
@VP	cellderived oligodendrocytes could myelinate injured spinal cord -LSB- 30 -RSB-	27225
@VP	could myelinate injured spinal cord -LSB- 30 -RSB-	27254
@VP	myelinate injured spinal cord -LSB- 30 -RSB-	27260
@VP	were significantly higher than GFP-positive cells in ESMN group	27362
@VP	might be due to the injured environment and rejection after transplantation	27463
@VP	be due to the injured environment and rejection after transplantation	27469
@VP	die after transplantation	27550
@VP	remained and established neuronal network	27594
@VP	remained	27594
@VP	established neuronal network	27607
@VP	extended axons into the peripheral nervous system	27690
@VP	were very low -LSB- 10 , 11 -RSB-	27797
@VP	derived dopamine neurons	27929
@VP	derived dopamine neuron	28161
@VP	suggested that in the presence of OEC	28189
@VP	significantly enhanced survival of neural stem	28228
@VP	were evident in the co-transplanted group	28372
@VP	evaluated the effect of cotransplantation of ESMN and OEC	28440
@VP	released NTF and cell adhesion molecules	28648
@VP	showed that tissue sparing and myelin ratio were higher than other groups	28702
@VP	were higher than other groups	28746
@VP	be due to the synergistic effects of two cell types in repairing of spinal cord	28796
@VP	repairing of spinal cord	28851
@VP	was higher than in ESMN group	28941
@VP	is the first report of positive effects of OEC on survival rate of ESMN	28977
@VP	secreted by OEC	29338
@VP	providing NTF support along with properties of antioxidant -LSB-	29456
@VP	derived from olfactory bulb , release NTFs such as NGF	29572
@VP	establishing connectivity with host cells -LSB- 38 -RSB-	29922
@VP	making connections -LSB- 38 -RSB-	30257
@VP	was not significant with ESMN and OEC groups	30296
@VP	have not established more functional synaptic connections	30388
@VP	established more functional synaptic connections	30397
@VP	was too short to show hindlimb improvement	30469
@VP	to show hindlimb improvement	30483
@VP	show hindlimb improvement	30486
@VP	to regenerate motor neurons in the spinal cord	30543
@VP	regenerate motor neurons in the spinal cord	30546
@VP	sending axons through the white matter toward muscle targets	30674
@VP	promoting neural regeneration , ESMN survival and functional recovery	30848
